Details of the Drug

General Information of Drug (ID: DMNH3PG)

Drug Name
Etoposide
Synonyms
etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposidum; Etoposido; Vepesid J; Eposin; Etoposidum [INN-Latin]; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP-16-213; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC 141540; CCRIS 2392; HSDB 6517; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); EINECS 251-509-1; NSC-141540; Eposide; Etopol; Etosid; Vepeside; Demethyl EpipodophyllotoxinEthylidine Glucoside; E0675; Demethyl-epiodophyllotoxin ethylidene glucoside; Epipodophyllotoxin VP-16213; Eposin (TN); Etopophos (TN); Trans-Etoposide; VePESID (TN); Vepesid (TN); DEMETHY-EPIPODOPHYLLOTOXIN, ETHYLIDENE GLUCOSIDE; VP-16 (TN); Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Etoposide (JP15/USP/INN); Etoposide [USAN:INN:BAN:JAN]; Eposin, Vepesid, VP-16, Toposar, Etoposide; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; 4-Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [1]
Adult acute monocytic leukemia N.A. Approved [1]
Adult kidney Wilms tumor N.A. Approved [1]
Beckwith-Wiedemann syndrome N.A. Approved [1]
Childhood kidney Wilms tumor N.A. Approved [1]
Hamartoma N.A. Approved [1]
Kidney neoplasm N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Small-cell lung cancer 2C25.Y Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Testicular cancer 2C80 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Neuroblastoma 2D11.2 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01CB01: Etoposide
L01CB: Podophyllotoxin derivatives
L01C: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
M05BC02: Etoposide
M05BC: Bone morphogenetic proteins
M05B: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
M05: DRUGS FOR TREATMENT OF BONE DISEASES
M: MUSCULO-SKELETAL SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 588.6
Logarithm of the Partition Coefficient (xlogp) 0.6
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 13
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.5 mL/min/kg [6]
Elimination
38% of drug is excreted from urine in the unchanged form [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 5.7 hours [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.2986 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.12% [6]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.18 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.22 mg/mL [5]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Cell death Not Available MAPK8 OTEREYS5 [8]
Cell death Not Available BCAP31 OTKSACR4 [8]
Cell death Not Available RBBP7 OTLB56HX [8]
Cytogenetic abnormality Not Available RB1 OT9VMY7B [8]
Cytogenetic abnormality Not Available HPRT1 OTOEEEXG [8]
Drug ineffective Not Available E7 OT6BIMFN [8]
Gene mutation Not Available BCL2 OT9DVHC0 [8]
Leukaemias Not Available KMT2B OTMMAZQX [8]
Neutropenia rs3095008 MACC1 OTV3DLX0 [9]
Neutropenia rs12987465 FSHR OT9MVMLI [9]
⏷ Show the Full List of 10 ADR Information of This Drug
Chemical Identifiers
Formula
C29H32O13
IUPAC Name
(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
Canonical SMILES
C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O
InChI
InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1
InChIKey
VJJPUSNTGOMMGY-MRVIYFEKSA-N
Cross-matching ID
PubChem CID
36462
ChEBI ID
CHEBI:4911
CAS Number
33419-42-0
UNII
6PLQ3CP4P3
DrugBank ID
DB00773
TTD ID
D0B7EB
VARIDT ID
DR00162
INTEDE ID
DR0669
ACDINA ID
D00258
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN ; TOP2B_HUMAN Modulator [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 3 (ABCC3) DTQ3ZHF MRP3_HUMAN Substrate [11]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [12]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [13]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [14]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [15]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [13]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [16]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [17]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [18]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [19]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [20]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [18]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [21]
Prostaglandin G/H synthase 2 (COX-2) DE492CE PGH2_HUMAN Substrate [22]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [22]
Glutathione S-transferase pi (GSTP1) DEK6079 GSTP1_HUMAN Substrate [23]
Glutathione S-transferase theta-1 (GSTT1) DE3PKUG GSTT1_HUMAN Substrate [23]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Gene/Protein Processing [24]
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial (CYP27B1) OTTK98BH CP27B_HUMAN Gene/Protein Processing [25]
3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B) OTOA8WU2 PDE4B_HUMAN Drug Response [26]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) OT1OG4QZ AAKB1_HUMAN Gene/Protein Processing [27]
5,6-dihydroxyindole-2-carboxylic acid oxidase OTRK49R4 TYRP1_HUMAN Drug Response [26]
5-hydroxytryptamine receptor 4 (HTR4) OTBIB44K 5HT4R_HUMAN Drug Response [26]
A-kinase anchor protein 12 (AKAP12) OTCVRDDX AKA12_HUMAN Drug Response [26]
Acid ceramidase (ASAH1) OT1DNGXL ASAH1_HUMAN Drug Response [26]
Actin, alpha skeletal muscle (ACTA1) OTOVGLPG ACTS_HUMAN Gene/Protein Processing [28]
Actin-binding Rho-activating protein (ABRA) OTBQ2C1J ABRA_HUMAN Gene/Protein Processing [28]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC1 3.0554 7.4438 1.439 23.181
EW-13 GDSC1 -3.2034 1.7883 -3.3865 76.0706
EW-7 GDSC1 -2.7604 1.1037 -2.8341 76.1429
ES8 GDSC1 -2.6016 -0.6337 -2.6027 80.3941
EW-16 GDSC1 -2.366 -0.5745 -2.3667 78.2908
ES1 GDSC1 -1.9643 1.6049 -2.0449 69.9628
SK-PN-DW GDSC1 -1.441 1.1199 -1.4626 66.6109
ES4 GDSC1 -0.9207 15.2351 -6.1057 53.0517
SK-ES-1 GDSC1; CTRP2 -0.9141 1.8738 -0.9417 38.2534
SK-N-MC CTRP2 -0.7152 1.8 -0.7335 36.8991
ES7 GDSC1 -0.4912 2.5306 -0.5924 55.4929
MHH-ES-1 GDSC1; CTRP2 -0.4312 1.6547 -0.4388 34.9706
RD-ES CTRP2 -0.3305 1.6059 -0.3357 34.291
HuO9 GDSC1 -0.0668 2.9031 -0.1941 50.7531
TC71 CTRP2 0.3611 2.7911 0.3221 29.791
A-673 GDSC1; CTRP2 0.5101 3.5423 0.3926 29.0624
EW-1 GDSC1 0.5672 3.3542 0.4081 43.5084
NOS-1 [Human HNSCC] GDSC1 1.4702 7.4202 -0.1 38.6233
EW-11 GDSC1 2.0726 8.9054 -0.1991 35.6703
NY GDSC1 2.1387 5.6593 1.3598 28.2902
HOS GDSC1; CTRP2 2.2907 6.6649 1.3991 20.0667
SaOS-2 GDSC1; CTRP2 2.3957 5.3305 2.016 17.4432
CHSA0108 GDSC1 2.595 8.5327 0.4777 30.5026
HuO-3N1 GDSC1 2.7718 4.8184 2.3726 18.1047
MG-63 GDSC1; CTRP2 2.9926 6.623 2.1484 15.2738
TC-71 GDSC1 3.0927 4.7315 2.7456 13.7596
EW-18 GDSC1 3.3743 10.7008 0.1149 28.6527
EW-3 GDSC1 3.5791 8.5115 1.3846 21.2605
ES6 GDSC1 3.671 8.1998 1.62 19.3811
U2OS GDSC1; CTRP2; CTRP1 3.8352 19.3767 -3.2922 29.9934
CAL-72 GDSC1 4.1939 13.015 -0.3469 27.4583
G-292 clone A141B1 GDSC1; CTRP2 4.2605 9.311 2.085 12.5321
CAL-78 GDSC1; CTRP2 4.281 11.7589 0.8837 17.2384
CHSA8926 GDSC1 4.3155 11.3673 0.5759 22.9846
EW-24 GDSC1 4.9224 8.7948 2.3211 10.1123
H-EMC-SS GDSC1 5.2036 11.7956 1.0541 17.5157
Hs 822.T CTRP2 5.4081 6.8718 4.2225 1.514
SJSA-1 GDSC1; CTRP2 6.535 19.7742 -1.2895 20.0778
CHSA0011 GDSC1 6.5817 9.3594 3.0443 1.9241
SW1353 CTRP2 6.9357 17.6691 0.0525 15.2904
ES5 GDSC1 8.1255 19.7273 -0.7483 18.5505
Hs 888.T CTRP2 10.4546 31.9125 -4.376 21.5742
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 215 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 -1.5107 3.0456 -1.6989 42.5787
MEC1 CTRP2 -0.837 3.0928 -0.9832 38.0859
JM1 GDSC1; CTRP2 -2.9375 0.5427 -2.9612 51.6351
MOLT-16 GDSC1; CTRP2 -5.4587 -2.2003 -5.4616 68.0918
DoHH2 GDSC1; CTRP2 -5.4207 2.8347 -5.8847 63.608
JVM-3 GDSC1; CTRP2 -4.6844 0.7744 -4.791 61.9573
EoL-1 GDSC1; CTRP2 -4.4939 -0.797 -4.5072 61.7161
SU-DHL-5 GDSC1; CTRP1 -3.8133 -2.5283 -3.8133 94.2638
SEM CTRP2 -3.8012 -1.4846 -3.8018 57.411
RCH-ACV CTRP2 -3.787 0.335 -3.8251 57.0518
HuNS1 CTRP2 -3.4452 1.2763 -3.5356 54.7459
KE-37 GDSC1; CTRP2 -3.2849 -0.6847 -3.2874 53.9667
SUP-B15 GDSC1; CTRP2 -3.2493 -0.8924 -3.2505 53.7372
SU-DHL-8 GDSC1; CTRP2 -3.2319 0.8257 -3.2788 53.503
RPMI-8402 GDSC1; CTRP2 -3.0874 0.4 -3.1092 52.6169
GA-10 GDSC1; CTRP2 -3.0717 3.1054 -3.3936 52.2261
SIG-M5 GDSC1; CTRP2 -2.8586 -0.5669 -2.8599 51.1363
MV4-11 GDSC1; CTRP2 -2.8151 -0.0614 -2.8208 50.8437
NALM-6 GDSC1; CTRP2 -2.5898 0.1185 -2.5959 49.348
697 GDSC1; CTRP2 -2.5886 -0.0866 -2.5921 49.3389
KE-97 CTRP2 -2.5371 1.1335 -2.5778 49.0158
Farage GDSC1 -2.5366 2.7117 -2.8276 70.6529
OCI-Ly19 GDSC1; CTRP2 -2.5258 0.6055 -2.5423 48.9289
CCRF-CEM GDSC1 -2.4838 0.4545 -2.5046 76.5141
Loucy GDSC1 -2.4836 0.2157 -2.496 77.2003
CML-T1 CTRP2 -2.4828 -0.3339 -2.4839 48.6321
BV-173 GDSC1; CTRP2 -2.407 4.1084 -2.8867 48.4032
Reh GDSC1 -2.3693 0.3841 -2.3848 75.9424
QIMR-WIL GDSC1 -2.2914 0.0119 -2.2966 76.3301
NU-DHL-1 CTRP2 -2.2762 4.1092 -2.7443 47.6415
P12-Ichikawa GDSC1; CTRP2 -2.268 0.3768 -2.2747 47.2093
MOLT-4 GDSC1 -2.2299 -0.2826 -2.2315 76.4738
MOLM-13 GDSC1; CTRP2 -2.2123 3.0836 -2.461 47.0992
NU-DUL-1 GDSC1; CTRP2; CTRP1 -2.204 0.7329 -2.2179 46.8528
RPMI-6666 GDSC1; CTRP2 -2.0989 4.473 -2.641 46.666
RS4;11 GDSC1; CTRP2 -2.0767 0.3976 -2.0816 45.9328
NB4 GDSC1 -1.8768 0.7848 -1.8956 71.1578
Kasumi-2 CTRP2 -1.872 1.0496 -1.8894 44.5975
EB1 CTRP2 -1.8694 3.3645 -2.142 44.9972
SU-DHL-4 GDSC1; CTRP2; CTRP1 -1.8541 2.7542 -2.0211 44.8039
Ki-JK CTRP2 -1.8392 4.4072 -2.341 45.1039
BDCM CTRP2 -1.8093 6.8989 -3.0762 45.6831
SKM-1 CTRP2; CTRP1 -1.7625 0.1746 -1.7635 43.8901
SU-DHL-1 GDSC1; CTRP2 -1.7609 1.1249 -1.7785 43.8601
ML-2 GDSC1 -1.6697 2.3887 -1.8338 66.1626
ALL-SIL GDSC1; CTRP2 -1.6425 1.112 -1.657 43.065
WSU-DLCL2 GDSC1; CTRP2; CTRP1 -1.5917 1.1716 -1.6069 42.791
OCI-Ly3 CTRP2 -1.5902 0.8018 -1.5963 42.6942
DEL GDSC1; CTRP2 -1.4666 0.813 -1.4715 41.8672
MHH-CALL-4 CTRP2 -1.4632 3.4863 -1.7258 42.421
MOLM-6 CTRP2 -1.3671 4.5149 -1.8534 42.2331
HC-1 GDSC1 -1.366 2.5224 -1.5289 63.6136
WIL2 NS GDSC1 -1.3618 1.5846 -1.4101 65.1335
KMS-34 CTRP2 -1.3417 0.4254 -1.3424 41.0213
CESS GDSC1 -1.3398 0.6762 -1.3453 66.167
KMS-21-BM CTRP2 -1.2912 1.2951 -1.3044 40.7223
CTV-1 GDSC1 -1.2724 0.9993 -1.2849 65.0912
Mino CTRP2 -1.2706 0.6984 -1.2726 40.551
ATN-1 GDSC1 -1.2612 -0.4866 -1.2612 65.7635
EB2 GDSC1 -1.232 0.5088 -1.2341 65.1168
TALL-1 [Human adult T-ALL] CTRP2 -1.2244 5.6202 -2.014 41.8974
Karpas-231 GDSC1 -1.2147 0.0789 -1.2149 65.1203
SUP-M2 GDSC1 -1.1996 0.8125 -1.2059 64.5087
NKM-1 GDSC1 -1.1506 2.3854 -1.2766 62.0231
Hs 611.T CTRP2 -1.1074 2.5859 -1.2042 39.733
Hs 445 GDSC1 -1.0684 2.0527 -1.1464 61.7265
MOTN-1 CTRP2 -1.0593 2.1913 -1.1144 39.3
MOLP-8 GDSC1; CTRP2 -1.0493 4.9822 -1.6328 40.4725
OCI-AML-3 GDSC1; CTRP2; CTRP1 -1.0293 1.2728 -1.0371 39.0264
KHM-1B CTRP2 -0.9945 3.0406 -1.1442 39.1302
M-07e CTRP2 -0.9805 2.9953 -1.1225 39.0179
U-937 CTRP2; CTRP1 -0.9186 1.3989 -0.9277 38.293
NCO2 CTRP2 -0.9169 3.9865 -1.2363 39.0564
Ri-1 CTRP2 -0.9128 5.641 -1.6813 40.016
THP-1 GDSC1; CTRP2; CTRP1 -0.9103 1.5679 -0.9242 38.2529
MM1.S CTRP2 -0.8543 0.7556 -0.855 37.7699
BC-1 GDSC1 -0.8457 3.2041 -1.0941 58.3506
Namalwa GDSC1; CTRP2 -0.7897 2.0355 -0.8224 37.4408
PF-382 GDSC1; CTRP2 -0.7161 2.0015 -0.7442 36.9362
OCI-AML-2 GDSC1 -0.7049 1.5812 -0.7272 58.4146
JSC-1 GDSC1 -0.6753 3.6002 -0.9989 56.4988
SR GDSC1; CTRP2 -0.6467 3.6568 -0.8748 37.0656
KMS-26 CTRP2 -0.6214 2.7373 -0.7067 36.483
MJ CTRP2 -0.5513 3.7785 -0.7953 36.4869
KM-H2 GDSC1; CTRP2 -0.5322 2.4723 -0.5862 35.7933
ALL-PO GDSC1 -0.4422 2.8718 -0.5931 54.7913
TUR GDSC1 -0.4345 2.1842 -0.4908 55.0575
MHH-CALL-3 CTRP2 -0.4192 12.4535 -3.9262 41.526
KMS-27 CTRP2 -0.3994 0.8591 -0.3995 34.7334
A4/Fukuda GDSC1; CTRP2 -0.3929 3.2569 -0.5321 35.1332
Kasumi-1 GDSC1; CTRP2 -0.3645 6.6338 -1.4232 37.3714
EM-2 GDSC1; CTRP2 -0.3397 3.7054 -0.5518 35.0043
SUP-T1 GDSC1; CTRP2 -0.3242 3.2057 -0.4508 34.6388
SU-DHL-16 GDSC1 -0.288 2.9656 -0.4432 53.1447
DND-41 GDSC1; CTRP2 -0.272 2.0444 -0.2889 33.9392
L-540 GDSC1; CTRP2 -0.1861 1.5503 -0.1889 33.3197
OCI-AML-5 GDSC1; CTRP2 -0.1592 3.7894 -0.3727 33.8187
Peer CTRP2 -0.1377 4.2747 -0.4537 33.9932
SCC-3 GDSC1 -0.1341 0.9346 -0.1343 51.6749
KMS-28BM CTRP2 -0.1169 7.4007 -1.4448 36.5317
SU-DHL-10 GDSC1; CTRP2 -0.1089 3.0691 -0.2025 33.1036
P30/OHK GDSC1 -0.0822 1.646 -0.0909 51.0143
SUP-T11 CTRP2 -0.0336 4.7693 -0.4654 33.6646
SUP-HD1 GDSC1; CTRP2 0.0088 4.1027 -0.2552 32.8698
Granta-519 GDSC1; CTRP2 0.0702 3.5713 -0.085 32.114
KOPN-8 GDSC1 0.1721 5.8388 -0.7922 48.6021
H9 GDSC1 0.173 2.5791 0.1084 47.9473
MC116 GDSC1; CTRP2 0.1794 4.1958 -0.0903 31.7628
Ci-1 CTRP2 0.1802 2.5143 0.1533 30.9568
HEL 92.1.7 CTRP2 0.185 1.888 0.181 30.8483
Mono-Mac-1 CTRP2 0.199 3.3797 0.0838 31.1259
SU-DHL-6 GDSC1; CTRP2 0.3143 4.037 0.0907 35.3442
MY-M12 GDSC1 0.4462 3.8242 0.1682 45.2013
Daudi GDSC1; CTRP2 0.4517 6.3747 -0.4504 31.9706
KMS-12-BM GDSC1; CTRP2 0.5362 4.8185 0.143 29.8164
AML-193 CTRP2 0.5421 2.2449 0.5358 28.4736
HPB-ALL CTRP2 0.5436 3.7376 0.3966 28.9391
JVM-2 GDSC1; CTRP2 0.582 4.3169 0.3202 29.0732
NOMO-1 GDSC1; CTRP1 0.604 2.5809 0.5876 47.8549
PL21 CTRP2; CTRP1 0.6121 3.1736 0.5509 28.2698
L-363 GDSC1; CTRP2 0.6655 4.3014 0.4146 28.4822
BL-70 CTRP2; CTRP1 0.6758 4.8909 0.2785 28.9872
OCI-M1 GDSC1; CTRP2 0.6798 2.7865 0.6543 27.6195
KYO-1 CTRP2 0.6884 2.4612 0.6787 27.5091
HL-60 GDSC1; CTRP2 0.693 2.4564 0.6836 27.4774
CMK CTRP2 0.7651 4.23 0.5391 27.7359
MOLM-16 CTRP2; CTRP1 0.7707 4.4059 0.5072 27.9054
P31/FUJ GDSC1; CTRP2 0.78 3.4821 0.6904 27.1688
CTB-1 GDSC1 0.8324 7.8632 -0.9459 44.2518
GDM-1 GDSC1; CTRP1 0.839 5.107 0.3945 46.07
A3/Kawakami GDSC1; CTRP2 0.8479 1.8902 0.8477 26.4132
VL51 GDSC1 0.8523 5.9526 -0.1125 42.6161
ST486 GDSC1; CTRP2 0.8649 3.5025 0.7782 26.5929
L-428 GDSC1; CTRP2 0.8945 3.4731 0.8137 26.3753
Jurkat CTRP2 0.9095 2.4158 0.9048 26.0174
P32/ISH GDSC1 0.9177 3.2734 0.8031 39.1282
BE-13 GDSC1 1.045 4.2987 0.6888 38.6939
HuT 78 CTRP2 1.0768 5.2752 0.5994 26.5422
BALL-1 GDSC1 1.0936 3.016 1.0326 36.6852
RPMI-8226 GDSC1; CTRP2; CTRP1 1.1022 3.9655 0.9603 25.2819
DB GDSC1; CTRP2 1.1458 4.8154 0.8092 25.5918
SET-2 CTRP2 1.1655 2.9337 1.1482 24.3522
U266B1 GDSC1; CTRP2 1.1783 5.3153 0.6973 25.885
Karpas-422 GDSC1; CTRP2 1.1795 4.4025 0.9509 24.9883
MOLP-2 CTRP2 1.212 4.7307 0.9043 25.0506
ARH-77 GDSC1 1.2122 3.887 0.9876 36.1069
KMS-20 CTRP2 1.2153 3.7002 1.1246 24.2699
JURL-MK1 GDSC1; CTRP2 1.2691 3.4904 1.2098 23.8037
Jiyoye GDSC1 1.27 3.7002 1.0969 35.132
MOLT-3 CTRP2 1.3169 1.708 1.3169 23.2843
BC-3 GDSC1 1.3336 3.7437 1.1558 34.3809
RL GDSC1; CTRP2 1.3489 5.0315 0.9695 24.3959
TF-1 CTRP2 1.3576 3.7482 1.2699 23.3107
Pfeiffer CTRP2 1.3791 2.9676 1.3666 22.9112
HEL GDSC1; CTRP2 1.3835 3.6551 1.3108 23.0864
KMS-11 CTRP2; CTRP1 1.4291 6.9448 0.3825 26.3047
NK-92MI GDSC1 1.5206 3.8754 1.3271 32.1794
HAL-01 GDSC1 1.5919 3.6894 1.4498 30.9887
EHEB GDSC1; CTRP2 1.6446 8.9919 -0.2773 27.7773
Ku812 GDSC1; CTRP2 1.6576 5.9996 0.9838 23.4164
BL-41 GDSC1; CTRP2 1.7007 4.7384 1.4356 21.6486
LC4-1 GDSC1 1.7217 6.2425 0.6778 34.2749
NCI-H929 CTRP2 1.7383 5.1193 1.3679 21.7781
Karpas-299 GDSC1 1.7501 3.454 1.6692 28.6366
MLMA GDSC1 1.7815 5.1261 1.1995 31.2928
MEG-01 GDSC1 1.7962 5.5925 1.0294 32.126
EJM GDSC1; CTRP2; CTRP1 1.8096 4.0229 1.7132 20.413
WSU-NHL GDSC1 1.8799 8.7977 -0.3337 37.0656
CA46 GDSC1; CTRP2 1.9919 6.1327 1.293 21.3075
HH [Human lymphoma] GDSC1; CTRP2 1.9922 6.684 1.0769 22.1092
HD-MY-Z CTRP2 2.0187 5.475 1.5587 20.2442
RPMI-8866 GDSC1 2.1595 4.2347 1.9227 24.5616
KCL-22 GDSC1; CTRP2 2.2372 5.3461 1.8388 18.5655
JeKo-1 CTRP2 2.3567 4.9618 2.0892 17.2898
LAMA-84 GDSC1; CTRP2 2.4392 6.1395 1.7674 18.2538
OCI-Ly10 CTRP2; CTRP1 2.4474 5.8044 1.9093 17.7815
AMO1 GDSC1; CTRP2; CTRP1 2.4479 6.5224 1.6287 18.8458
KMOE-2 GDSC1 2.5591 5.1414 2.0164 21.7361
K-562 GDSC1; CTRP2 2.5848 5.5975 2.1279 16.4757
TK [Human B-cell lymphoma] GDSC1 2.6339 3.9803 2.5144 17.8592
OPM-2 GDSC1; CTRP2 2.6466 7.2064 1.538 18.5709
PL-21 GDSC1 2.6536 5.5119 1.9554 21.6753
HDLM-2 GDSC1; CTRP2 2.6824 5.5872 2.2367 15.7858
Sc-1 GDSC1 2.7271 7.8942 0.9118 27.7584
KMS-18 CTRP2 2.7387 6.8601 1.7838 17.3728
GR-ST GDSC1 2.753 5.6382 2.0004 20.8604
JJN-3 GDSC1; CTRP2 2.8416 7.5731 1.5725 17.9271
MHH-PREB-1 GDSC1 2.9101 8.5678 0.7544 27.7106
SK-MM-2 GDSC1 2.9485 8.4807 0.8326 27.1362
HT GDSC1; CTRP2 2.9788 6.1229 2.345 14.5433
KO52 CTRP2 3.0003 4.7945 2.8388 12.6196
Ramos.2G6.4C10 GDSC1 3.1415 5.7495 2.3365 16.5637
Raji GDSC1 3.1449 7.8899 1.3033 23.6118
KG-1 GDSC1 3.2636 5.7111 2.4735 14.981
Mono-Mac-6 GDSC1; CTRP2 3.4379 14.4957 -1.2206 25.9777
U-698-M GDSC1 3.5589 6.0504 2.5874 12.8304
RC-K8 GDSC1 3.75 8.5106 1.5331 19.6332
YT GDSC1 3.9797 9.5989 1.1836 20.9046
DG-75 GDSC1 3.9958 5.2338 3.3796 4.9085
P3HR-1 CTRP2 4.0218 12.0816 0.4965 19.2171
MN-60 GDSC1 4.4857 8.7687 2.0073 13.7308
L-1236 GDSC1; CTRP2 4.5137 10.5113 1.7071 13.5438
KY821 GDSC1 4.5141 6.7559 3.0235 6.0244
Karpas-45 GDSC1 4.7068 9.0643 2.0301 12.8514
ME1 GDSC1 4.7784 6.8056 3.1808 4.1251
IM-9 GDSC1 4.9852 11.1528 1.2078 17.3006
VAL GDSC1 5.0018 19.0615 -2.713 31.902
ME1 CTRP2 5.0311 8.182 3.3027 5.9131
ROS-50 GDSC1 5.2355 8.5463 2.6556 6.8333
F-36P CTRP2 5.6429 10.8388 2.4565 8.3727
LP-1 GDSC1; CTRP2; CTRP1 5.7225 12.7106 1.602 11.7635
Karpas-620 GDSC1; CTRP2 6.3997 11.1297 2.8546 5.5965
KMM-1 CTRP2 6.561 14.1608 1.4994 10.696
Toledo CTRP2 6.9908 22.1979 -2.142 21.5833
REC-1 CTRP2 7.4099 10.001 3.9268 0.8212
⏷ Show the Full List of 215 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE15 CTRP2 1.373 3.3227 1.3368 23.0319
TE8 CTRP2 3.2582 7.3838 2.0765 14.8759
KYSE-270 GDSC1 -1.8735 2.5554 -2.0811 67.222
TE-15 GDSC1 0.3383 2.7341 0.265 45.9844
TE-5 GDSC1; CTRP2 1.3233 5.3178 0.8544 24.8843
TE-9 GDSC1; CTRP2 1.5497 4.5406 1.3213 22.523
TE-11 GDSC1; CTRP2 2.6348 5.3015 2.2852 15.7423
KYSE-510 GDSC1; CTRP2 2.7074 6.5097 1.9002 17.0051
TE-8 GDSC1 2.888 9.5685 0.2423 30.1724
T.T GDSC1 3.1489 6.2087 2.1253 18.0837
KYSE-150 GDSC1; CTRP2 3.1585 8.4705 1.4692 17.5338
EC-GI-10 GDSC1; CTRP2 3.6555 7.665 2.3333 12.8699
COLO 680N GDSC1; CTRP2 3.6755 8.4362 1.9808 14.2567
TE-4 CTRP2 3.8713 12.2992 0.2554 20.4004
TE-1 GDSC1; CTRP2 3.911 6.3275 3.2136 8.6683
TE-14 CTRP2 3.9861 7.5253 2.7153 10.5307
KYSE-180 GDSC1; CTRP2 4.6054 6.2044 3.9341 4.0852
TE-6 GDSC1; CTRP2 4.6338 7.6603 3.2338 6.9658
KYSE-520 GDSC1; CTRP2 4.7545 8.1873 3.0731 7.401
KYSE-30 CTRP2 4.9831 11.9832 1.3649 13.9715
TE-10 GDSC1; CTRP2 5.2153 7.5879 3.7407 3.7602
KYSE-140 GDSC1; CTRP2 5.2191 10.0358 2.5278 8.8144
OE21 GDSC1; CTRP2 5.7745 11.4201 2.2683 8.9221
KYSE-70 GDSC1; CTRP2 6.0918 12.5514 1.9467 9.6964
OE19 GDSC1; CTRP2 6.1134 10.8696 2.7836 6.2922
KYSE-450 GDSC1; CTRP2 6.5261 9.7618 3.5736 2.6619
OE33 GDSC1; CTRP2 6.6837 13.0378 2.1315 8.0545
KYSE-410 GDSC1; CTRP2 7.0577 17.5529 0.1989 14.6052
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 3.5017 7.0447 2.4753 12.667
MZ-PC-1 GDSC1 -0.5693 4.0396 -0.9975 55.2614
KP-4 GDSC1; CTRP2 0.3973 3.0004 0.3414 29.606
KP-1N GDSC1 1.1947 4.4798 0.7952 37.1589
HuP-T4 GDSC1; CTRP2 1.2504 5.8619 0.5938 26.0282
Panc 03.27 GDSC1; CTRP2 1.3856 4.9186 1.0421 24.0246
Capan-1 GDSC1; CTRP2 1.6546 6.4344 0.8173 24.0287
MIA PaCa-2 GDSC1; CTRP2 1.8012 4.7816 1.5337 20.9884
PaTu 8988t GDSC1; CTRP2 2.3494 3.5866 2.3353 16.4437
SW1990 GDSC1; CTRP2 2.7407 6.3533 2.0001 16.528
L3.3 CTRP2 2.7666 4.2931 2.6966 13.8526
PSN1 GDSC1; CTRP2 2.9405 5.5657 2.5222 13.97
KP-2 GDSC1; CTRP2 3.1217 6.6186 2.2833 14.4024
PK-59 CTRP2 3.3132 6.6997 2.4432 13.2716
PL4 GDSC1 3.4315 7.94 1.5382 20.9004
DAN-G GDSC1; CTRP2 3.639 7.4853 2.403 12.625
QGP-1 CTRP2 3.9242 8.1383 2.3588 12.1414
Panc 10.05 GDSC1; CTRP2 4.1614 8.8207 2.2398 12.1067
YAPC GDSC1; CTRP2 4.2087 7.0302 3.1647 8.1647
SUIT-2 GDSC1; CTRP2 4.3265 9.0799 2.2582 11.6782
BxPC-3 GDSC1; CTRP2 4.4032 7.8026 2.9609 8.5885
SU.86.86 GDSC1; CTRP2 4.4281 9.0494 2.3625 11.0336
HPAC GDSC1; CTRP2 4.548 6.4199 3.7759 4.8699
HPAF-II GDSC1; CTRP2 4.7072 8.7307 2.7616 8.8019
TCC-Pan2 CTRP2 4.7146 7.0256 3.62 5.1794
PaTu 8988s CTRP2 4.7866 9.3035 2.542 9.565
HuP-T3 GDSC1; CTRP2 4.8588 7.8254 3.341 6.073
CFPAC-1 GDSC1; CTRP2 4.9458 7.695 3.4772 5.3363
KP-3 GDSC1; CTRP2 5.099 8.9554 2.9711 7.1809
Panc 08.13 GDSC1; CTRP2 5.3439 7.3036 3.9731 2.5997
Panc 04.03 GDSC1; CTRP2 5.4893 9.3051 3.0984 5.9759
Panc 02.03 GDSC1; CTRP2 5.6792 8.3642 3.6926 3.7456
SNU-410 CTRP2 5.7129 10.4533 2.699 7.2607
AsPC-1 GDSC1; CTRP2 5.7386 11.6329 2.1362 9.5187
Capan-2 GDSC1; CTRP2 5.7912 10.5898 2.6895 7.1733
PaTu 8902 GDSC1; CTRP2; CTRP1 5.9005 14.0744 1.0622 13.527
SNU-213 CTRP2 6.4086 12.0225 2.4314 7.2707
Panc 05.04 CTRP2 6.7096 14.036 1.6661 9.8262
Hs 766T GDSC1; CTRP2 6.9458 12.555 2.5378 6.1028
PK-45H CTRP2 7.562 14.3775 2.077 7.063
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 76 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 6.094 10.6981 2.8531 6.9506
COLO 679 GDSC1 -2.5823 3.1096 -2.9614 69.9531
DJM-1 GDSC1 -2.2629 7.2262 -3.9239 62.0137
CHL-1 GDSC1 -0.4297 2.9681 -0.5966 54.6111
A-431 GDSC1 -0.2406 1.4698 -0.2472 52.9713
A2058 GDSC1; CTRP2 0.2608 3.1328 0.1825 30.5913
CJM [Human melanoma] CTRP2 0.6387 3.3522 0.557 28.0837
HMV-II GDSC1 0.7214 8.2131 -1.215 45.2569
Hs 944.T CTRP2 0.8608 5.9222 0.1515 28.7472
MZ-MEL-2 GDSC1 0.8848 11.6066 -2.633 45.7148
COLO 800 GDSC1; CTRP2 1.1065 3.5872 1.0245 24.9658
WM278 GDSC1 1.2648 4.9833 0.6986 37.1008
RPMI-7951 GDSC1; CTRP2 1.3795 4.3188 1.1876 23.5277
IST-MEL1 GDSC1 1.4143 8.2867 -0.5519 40.1349
A-388 GDSC1 1.4604 9.6783 -1.1586 41.1588
IGR-39 CTRP2 1.5644 4.284 1.3962 22.2125
G-361 GDSC1; CTRP2 1.8124 7.9622 0.3505 25.2292
IGR-37 GDSC1; CTRP2 1.8672 4.7379 1.6174 20.4854
MZ-MEL-7 GDSC1 1.8745 9.2305 -0.545 37.6895
WM35 GDSC1 1.9101 6.0893 0.9386 31.9224
UACC-62 GDSC1; CTRP2 1.9461 9.6607 -0.2803 26.9422
CP66-MEL GDSC1 2.2908 9.9 -0.4725 35.4717
A-375 GDSC1; CTRP2; CTRP1 2.3177 7.4471 1.1015 21.1992
Hs 294T CTRP2 2.4496 6.7 1.5512 19.0507
SH-4 GDSC1 2.4751 10.1064 -0.4016 34.4052
IPC-298 GDSC1; CTRP2 2.5119 5.5312 2.073 16.8921
COLO 829 GDSC1; CTRP2 2.5274 14.9725 -2.2811 30.7466
Hs 852.T CTRP2; CTRP1 2.6647 9.5074 0.5062 22.4675
HMCB CTRP2 2.6778 6.8195 1.7381 17.7129
MMAc-SF GDSC1 2.6951 9.2234 0.2345 31.0775
MeWo GDSC1; CTRP2 2.9045 5.4947 2.5094 14.1212
G-mel GDSC1 3.0028 8.2259 1.0076 25.9563
M14 GDSC1 3.0562 5.1427 2.5301 15.5281
WM983B CTRP2 3.0758 6.239 2.3985 14.0722
WM266-4 CTRP2 3.1447 10.4196 0.5185 21.1528
Hs 938.T GDSC1 3.2794 10.4867 0.1382 28.9404
WM1552C GDSC1 3.2942 11.0375 -0.1229 29.9298
LOX-IMVI GDSC1; CTRP2 3.4641 10.3197 0.8648 19.1251
451Lu GDSC1 3.6716 7.1573 2.1399 15.7473
WM793 GDSC1; CTRP2 3.7766 11.3073 0.6629 19.1574
WM88 CTRP2 3.8076 10.2326 1.2224 16.9763
SK-MEL-2 GDSC1 4.0436 6.0974 2.9874 7.8271
Hs 936.T CTRP2 4.1032 8.8766 2.1597 12.5631
SK-MEL-1 GDSC1; CTRP2; CTRP1 4.1532 8.987 2.1598 12.543
Mel Ho GDSC1; CTRP2 4.2438 9.8374 1.8085 13.6959
SK-MEL-3 GDSC1; CTRP2 4.2902 7.419 3.049 8.4643
A101D GDSC1; CTRP2 4.2903 10.2279 1.655 14.2172
GAK GDSC1 4.3948 16.6627 -2.0054 31.94
SK-MEL-30 GDSC1; CTRP2 4.5775 7.7217 3.1545 7.4137
SK-MEL-5 GDSC1; CTRP2; CTRP1 4.6512 9.9032 2.1388 11.5929
WT2-iPS GDSC1; CTRP2 4.7377 7.8277 3.2387 6.7377
SK-MEL-24 GDSC1; CTRP2 4.9837 11.0466 1.8334 12.1047
IGR-1 GDSC1; CTRP2 5.0451 8.7525 3.0292 7.0355
LB2518-MEL GDSC1 5.1415 16.17 -1.1619 27.3491
WM115 GDSC1; CTRP2 5.4961 12.6958 1.4215 12.7922
MDA-MB-435S CTRP2 5.5057 10.1365 2.7001 7.5995
SK-MEL-28 GDSC1; CTRP2; CTRP1 5.6511 8.6404 3.5531 3.94
Malme-3M CTRP2 5.6541 11.3897 2.1925 9.4332
SK-MEL-31 CTRP2 5.6754 8.5532 3.5992 3.6318
Hs 940.T GDSC1; CTRP2 5.7315 8.5028 3.6615 3.302
COLO 783 GDSC1 5.8863 7.23 3.5623 0.342
WM1799 CTRP2 5.9719 12.0992 2.0806 9.3559
Hs 839.T CTRP2 6.0032 8.2364 3.9571 1.8221
HT-144 GDSC1; CTRP2 6.0622 10.427 2.9621 5.6465
Hs 895.T CTRP2 6.1083 8.284 3.9961 1.5725
K029AX CTRP2 6.1541 12.4348 2.0495 9.1865
Mel JuSo GDSC1; CTRP2 6.2443 10.9513 2.8348 5.8949
UACC-257 GDSC1; CTRP2 6.3871 12.9532 1.9642 9.1591
VMRC-MELG GDSC1 6.4132 7.7356 3.5774 0.1352
LB373-MEL-D GDSC1 6.4271 14.2929 0.7089 16.0037
CP50-MEL-B GDSC1 6.7101 7.8734 3.6314 0.0395
Hs 688(A).T CTRP2 7.8216 19.8135 -0.3562 15.2329
Hs 934.T CTRP2 8.9819 30.643 -4.818 24.3263
COLO 792 GDSC1; CTRP2 10.0325 21.8412 0.1512 10.6774
RVH-421 GDSC1; CTRP2 13.2374 32.3158 -2.7171 14.8262
EquiPSC Line K2 GDSC1 5.1189 8.1527 2.7657 6.3261
⏷ Show the Full List of 76 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-50 GDSC1 -0.6433 3.4406 -0.9264 56.3431
HCE-4 GDSC1 -0.3501 2.3512 -0.4195 54.0467
KYSE-220 GDSC1 0.0501 3.1447 -0.1108 49.4427
TE-12 GDSC1 6.1285 18.3415 -1.4834 25.7104
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; CTRP2 4.1064 9.0279 2.0878 12.8518
Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SK-N-MC-IXC GDSC1 -3.0431 -1.7986 -3.0431 86.8392
IMR-32 CTRP2 -2.4945 -0.352 -2.4956 48.7104
NB69 GDSC1 -2.2488 3.2694 -2.6348 67.9297
IMR-5 GDSC1 -1.5677 -0.2606 -1.5678 69.4737
NH-6 CTRP2 -1.1763 2.1595 -1.2342 40.084
MHH-NB-11 GDSC1; CTRP2 -1.1258 1.1665 -1.1329 39.6014
CHP-212 GDSC1; CTRP2 -0.6646 4.1481 -0.9981 37.4687
NH-12 GDSC1 -0.3612 4.9112 -1.0363 53.078
SJNB-12 GDSC1 -0.2298 10.9999 -3.4403 51.0697
SK-N-SH GDSC1; CTRP2 0.0239 5.1096 -0.4986 33.5638
SJNB-14 GDSC1 0.8685 6.3806 -0.2694 42.8476
SK-N-BE(2) CTRP2 0.9082 7.0345 -0.211 29.7707
SJNB-17 GDSC1 1.0122 7.9337 -0.7948 42.9385
CHP-126 GDSC1; CTRP2 1.2702 4.3153 1.0695 24.2871
SJNB-13 GDSC1 1.3574 6.6304 0.1339 38.5867
SiMa GDSC1; CTRP2 1.597 4.8429 1.2941 22.4741
NB1 GDSC1; CTRP2 1.6814 5.4498 1.2011 22.555
Kelly GDSC1; CTRP2 1.8723 5.3836 1.4302 21.1498
KP-N-YS GDSC1 2.0589 7.5408 0.4332 33.416
NB(TU)1 GDSC1 2.5959 6.6649 1.3715 25.7984
GOTO GDSC1 2.7372 7.2346 1.239 25.8911
GI-ME-N GDSC1 2.7423 15.3568 -2.7578 38.7093
KP-N-YN GDSC1; CTRP2 3.4724 9.5776 1.2353 17.6943
SK-N-BE(2)-M17 GDSC1 3.4837 6.2947 2.3983 14.5895
SJNB-10 GDSC1 3.6351 10.1323 0.6247 25.2771
SK-N-DZ GDSC1; CTRP2 3.6374 7.4165 2.434 12.5027
SK-N-AS GDSC1; CTRP2 3.8974 8.1596 2.3233 12.3482
SJNB-5 GDSC1 4.0485 9.6873 1.1967 20.5695
SK-N-FI GDSC1; CTRP2 4.5295 6.9444 3.4992 6.0673
TGW GDSC1 4.6596 7.9985 2.5203 9.4244
SJNB-6 GDSC1 4.8399 14.7845 -0.7093 26.7049
SJNB-7 GDSC1 5.0381 8.9471 2.3291 9.7215
LA-N-6 GDSC1 5.9989 7.8322 3.3845 0.9092
⏷ Show the Full List of 33 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-478 CTRP2 0.9369 3.7283 0.8216 26.2109
SNU-1079 CTRP2 2.234 8.0983 0.7213 22.7481
HuCC-T1 GDSC1; CTRP2 2.326 6.0637 1.6763 18.9182
SNU-1196 CTRP2 4.1309 7.0531 3.0807 8.6891
SNU-869 CTRP2 4.466 7.4484 3.1926 7.4858
SNU-245 CTRP2 4.9953 9.7159 2.5079 9.3084
HuH-28 CTRP2 5.4005 7.9962 3.6762 3.7296
SNU-308 CTRP2 5.5847 9.1875 3.2265 5.2925
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 90 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OCUB-M GDSC1 -3.4142 1.8451 -3.6212 76.6979
DU4475 GDSC1; CTRP2 -3.3873 0.8332 -3.4405 54.4764
EFM-19 GDSC1 -1.2329 12.3305 -5.0531 54.8111
MRK-nu-1 GDSC1 -1.2206 6.433 -2.5072 57.8508
SK-BR-3 CTRP2 -1.0497 6.4584 -2.1011 41.3248
HCC1599 GDSC1 -0.9483 0.8143 -0.9517 61.654
CAL-148 GDSC1 -0.4936 4.3021 -0.9897 54.4587
EFM-192A GDSC1 -0.2725 3.3759 -0.5083 52.8419
CAL-51 GDSC1; CTRP2 0.5406 4.151 0.3124 29.2341
AU565 GDSC1; CTRP2 0.838 4.9141 0.4459 27.823
MDA-MB-468 GDSC1; CTRP2 1.023 3.6557 0.9252 25.5768
HCC38 GDSC1; CTRP2 1.4653 4.1118 1.3238 22.7795
CAL-85-1 GDSC1; CTRP2 2.2217 5.3065 1.835 18.6256
HCC1569 GDSC1; CTRP2 2.3553 6.3542 1.5933 19.1503
HCC1954 GDSC1; CTRP2 2.5483 6.517 1.7306 18.0927
MDA-MB-157 GDSC1; CTRP2 2.6773 7.6012 1.3939 19.0465
BT-20 GDSC1; CTRP2 2.6948 5.655 2.2253 15.7934
HMC-1-8 CTRP2 2.8169 6.5607 1.993 16.3496
BT-549 GDSC1; CTRP2 3.0371 8.6056 1.2872 18.5421
ZR-75-30 GDSC1; CTRP2 3.283 9.3149 1.1844 18.3397
HCC1806 GDSC1; CTRP2 3.4646 7.0006 2.4588 12.8256
HCC2157 GDSC1 3.8495 9.4808 1.1332 21.6961
MDA-MB-436 GDSC1 3.8878 10.7675 0.5222 24.8056
MDA-MB-231 GDSC1; CTRP2 3.9974 7.5524 2.7127 10.5156
T-47D GDSC1; CTRP2 4.1059 12.9238 0.1507 20.2477
ZR-75-1 CTRP2 4.5929 10.2966 1.8821 12.6745
HCC1187 GDSC1 4.6141 7.4778 2.7426 7.8801
MDA-MB-175-VII GDSC1 4.6997 8.6791 2.2149 11.5535
Evsa-T GDSC1 4.8779 9.2372 2.0721 12.0243
MDA-MB-453 GDSC1; CTRP2 4.9743 7.2257 3.7343 4.2037
CAL-120 GDSC1; CTRP2 4.9976 10.0159 2.3599 9.9193
CAMA-1 GDSC1; CTRP2 5.0594 9.8613 2.4872 9.2754
HDQ-P1 GDSC1; CTRP2 5.0921 11.248 1.8211 11.9491
HCC1937 GDSC1; CTRP2 5.1199 10.8942 2.0203 11.088
HCC70 GDSC1 5.1878 8.2524 2.7635 6.1719
KPL-1 CTRP2 5.2337 6.9323 4.0759 2.3459
HCC1419 GDSC1; CTRP2 5.4019 7.6541 3.8439 3.0399
HCC1395 GDSC1; CTRP2 5.4482 10.9953 2.2299 9.6365
HCC1143 CTRP2 5.4555 8.4708 3.4837 4.4364
BT-483 GDSC1 5.5304 9.7952 2.2571 8.9126
COLO 824 GDSC1 5.5659 12.731 0.8608 17.5177
UACC-812 GDSC1 5.6189 11.8132 1.3465 14.5978
MCF-7 GDSC1; CTRP2; CTRP1 5.7182 14.4601 0.7291 15.0805
JIMT-1 GDSC1; CTRP2 5.7606 9.4259 3.2362 4.9811
MFM-223 GDSC1 5.8041 7.6285 3.3785 1.119
UACC-893 GDSC1 5.8678 9.0382 2.8146 4.3487
MDA-MB-415 GDSC1 5.8751 9.9551 2.4022 7.0964
HCC202 CTRP2 5.8841 8.1634 3.9192 2.098
BT-474 GDSC1; CTRP2 5.9785 7.7001 4.181 1.0578
HCC1428 GDSC1; CTRP2 6.0666 8.854 3.7124 2.6679
MDA-MB-361 GDSC1; CTRP2 6.1282 13.6013 1.4567 11.5593
Hs 578T GDSC1 6.1388 7.7302 3.4793 0.4604
HCC1500 GDSC1; CTRP2 6.8748 14.6789 1.4704 10.3231
Hs 578Bst CTRP2 7.1685 16.0118 1.0301 11.5154
MDA-MB-330 GDSC1 7.6784 18.7301 -0.571 18.8198
HCC2218 GDSC1; CTRP2 7.8825 16.5408 1.2631 9.6489
BT 239 CTRP2 -0.9021 5.4137 -1.5991 39.8072
BT 145 CTRP2 -0.2622 5.2401 -0.8492 35.5755
BT164 CTRP2 0.1898 5.1089 -0.3174 32.4453
BT 112 CTRP2 0.5195 6.3392 -0.3646 31.4891
BT 286 CTRP2 0.9144 10.8432 -1.8534 34.1118
BT 428 CTRP2 1.3311 3.0833 1.3109 23.257
BT 416 CTRP2 2.4244 4.3134 2.323 16.2444
BT 245 CTRP2 2.5191 6.4517 1.7267 18.1877
BT 271 CTRP2 2.6044 10.5301 -0.0476 24.4469
BT 231 CTRP2 2.7629 7.561 1.4985 18.4187
BT 333 CTRP2 3.4678 8.6064 1.7017 15.8677
BT 216 CTRP2 3.6316 7.7009 2.2931 13.09
BT 131 CTRP2 3.6574 9.7233 1.3357 16.8753
BT 187 CTRP2 3.8249 8.7269 1.9787 13.9227
BT 504 CTRP2 4.4119 9.9539 1.8975 12.9816
BT147 CTRP2 4.5898 12.6111 0.7228 17.1944
BT 330 CTRP2 4.7069 9.6046 2.3245 10.6268
BT 179 CTRP2 4.8279 7.9598 3.2482 6.5223
BT 224 CTRP2 4.8589 9.262 2.6228 9.0877
BT 172 CTRP2 5.0217 13.1418 0.8174 15.9841
BT 422 CTRP2 5.1633 6.9525 4.015 2.7067
BT 482 CTRP2 5.327 9.5275 2.8652 7.2198
BT 444 CTRP2 5.4337 9.0625 3.1766 5.7433
BT 328 CTRP2 5.5173 8.8821 3.3271 4.9846
BT 232 CTRP2 5.6588 14.1197 0.8403 14.7056
BT 440 CTRP2 5.8078 9.8908 3.0435 5.6968
BT 359 CTRP2 5.8113 15.0678 0.4879 15.7063
BT 248 CTRP2 5.9741 14.0339 1.1267 13.0805
BT 228 CTRP2 6.1123 13.3072 1.5899 11.069
BT 340 CTRP2 6.6695 15.1817 1.0784 12.1098
BT 320 CTRP2 6.7108 7.7484 4.4759 0.0554
BT 159 CTRP2 6.9442 13.01 2.321 6.9467
BT 498 CTRP2 7.2015 19.266 -0.5367 16.7541
BT 139 CTRP2 7.5671 19.374 -0.3237 15.5166
⏷ Show the Full List of 90 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 4.0888 7.401 2.8719 9.6492
Cancer Drug Sensitivity Data Curated from 68 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
AM-38 GDSC1; CTRP2 -11.4222 15.4867 -16.6423 66.653
H4 GDSC1 -1.6926 6.9593 -3.2128 59.7908
M059J GDSC1 -1.2765 2.7351 -1.4689 62.5592
KS-1 [Human Krukenberg tumour] GDSC1 -1.1568 16.3479 -6.8636 53.5497
MOG-G-UVW GDSC1 -0.4334 2.7437 -0.5623 54.7686
GI-1 GDSC1 -0.4069 2.38 -0.4832 54.6639
SK-MG-1 GDSC1 -0.1487 1.3326 -0.1516 51.849
D-423MG GDSC1 -0.0847 1.8493 -0.1015 51.0361
Daoy GDSC1; CTRP2 0.2847 4.1068 0.0438 30.9726
D283 Med GDSC1; CTRP2 0.3383 3.4555 0.2217 30.2032
D-566MG GDSC1 0.6479 2.4834 0.6182 42.0482
SF539 GDSC1; CTRP2 0.8565 4.1674 0.6521 27.0536
8-MG-BA GDSC1; CTRP2 1.3162 2.8313 1.3076 23.3175
SF126 GDSC1; CTRP2 1.3826 4.3931 1.1743 23.5651
Hs 683 GDSC1; CTRP2 1.4759 4.7302 1.1924 23.2104
YKG-1 GDSC1; CTRP2 1.5547 4.951 1.2174 22.8785
SF268 GDSC1; CTRP2 1.7521 6.0853 1.0539 22.8838
ONS-76 GDSC1; CTRP2 1.7701 4.7164 1.5171 21.1431
Onda 10 GDSC1 1.8365 6.3469 0.7508 33.264
U-251MG GDSC1; CTRP2 2.03 7.8214 0.6356 23.616
SF295 GDSC1; CTRP2 2.1484 5.2457 1.775 19.0637
LN-18 GDSC1; CTRP2 2.224 3.4885 2.2112 17.2758
LNZTA3WT4 GDSC1 2.2538 6.007 1.3279 27.8475
Onda 11 GDSC1 2.2872 7.9605 0.4587 32.1101
MOG-G-CCM GDSC1 2.3213 8.6507 0.1612 33.1539
DBTRG-05MG GDSC1; CTRP2 2.4055 8.6548 0.6411 22.5799
SNU-626 CTRP2 3.1057 5.3575 2.7755 12.541
CAS-1 GDSC1; CTRP2 3.4874 7.779 2.1165 14.1519
42-MG-BA GDSC1; CTRP2 3.5515 7.769 2.1834 13.7273
GB-1 GDSC1; CTRP2 3.5683 6.682 2.7086 11.5608
Becker GDSC1; CTRP2 3.7055 7.3417 2.5356 11.9255
KALS-1 GDSC1; CTRP2 3.8516 9.0157 1.8618 14.337
SNB-75 GDSC1; CTRP2 3.8613 7.9641 2.3848 12.1781
SW1088 GDSC1; CTRP2 3.8982 8.3575 2.2274 12.7404
KNS-60 CTRP2 3.954 8.3291 2.293 12.3448
D-247MG GDSC1 3.966 10.4228 0.7602 23.3099
GMS-10 CTRP2 3.9961 8.8528 2.0743 13.1488
KINGS-1 GDSC1 4.0583 5.6627 3.2168 5.9688
SNU-466 CTRP2 4.1099 6.6461 3.2574 8.0097
YH-13 GDSC1; CTRP2 4.1155 11.2724 0.9816 17.2228
SNU-738 CTRP2 4.1722 8.3686 2.4732 11.1178
A-172 GDSC1; CTRP2 4.3519 10.902 1.3726 15.2101
GOS-3 CTRP2 4.3789 11.2067 1.244 15.6564
M059K CTRP2 4.425 9.1575 2.306 11.2744
LN-405 GDSC1 4.4433 6.7479 2.9757 6.6033
D-542MG GDSC1 4.585 6.5814 3.1583 4.7938
GaMG GDSC1; CTRP2; CTRP1 4.6034 10.4086 1.8456 12.8873
D-336MG GDSC1 4.6654 11.1963 0.9403 19.8661
SNU-489 CTRP2 4.7214 8.4769 2.9005 8.1914
T98G GDSC1; CTRP2 4.8153 6.2859 4.0747 3.0684
SNU-201 CTRP2 4.8272 11.9908 1.2322 14.7923
SW1783 GDSC1; CTRP2 4.8719 12.272 1.1287 15.1029
LN-229 GDSC1; CTRP2; CTRP1 4.8866 10.2361 2.1696 11.004
KNS-42 GDSC1; CTRP2 4.9584 10.1138 2.2789 10.3286
CCF-STTG1 CTRP2 5.0581 6.6583 4.0816 2.6027
TM-31 CTRP2 5.0882 9.9071 2.4876 9.2205
PFSK-1 GDSC1 5.4963 12.8951 0.7294 18.4179
KNS-81 CTRP2 5.6021 8.8597 3.3992 4.5556
DK-MG GDSC1; CTRP2 5.6024 12.888 1.409 12.6501
NMC-G1 GDSC1; CTRP2 5.6509 10.4337 2.6625 7.5122
U-118MG GDSC1; CTRP2 5.6649 14.7345 0.5391 15.7882
D-263MG GDSC1 5.7011 7.2106 3.4955 0.6933
D-392MG GDSC1 5.9891 15.2601 -0.0706 20.8532
SNU-1105 CTRP2 6.0541 12.8866 1.7538 10.5225
U-87MG ATCC GDSC1; CTRP2 6.1199 11.1411 2.6565 6.7968
KG-1-C CTRP2 6.4666 11.2668 2.8338 5.5864
D-502MG GDSC1 6.5929 8.7785 3.2745 0.8849
KNS-81-FD GDSC1 7.0822 15.5707 0.5377 15.2865
⏷ Show the Full List of 68 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC1 1.4186 4.4764 1.0397 34.4458
TGBC24TKB GDSC1 5.819 8.4968 3.0254 3.0845
TGBC1TKB GDSC1 6.1245 13.93 0.6747 16.9609
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHUEM-2 CTRP2; CTRP1 -2.8901 2.595 -3.1075 51.2686
ESS-1 GDSC1; CTRP2 -0.6908 1.6146 -0.7019 36.7135
JHUEM-7 CTRP2 0.0556 4.9656 -0.4225 33.2261
MFE-296 GDSC1; CTRP2 1.081 4.0355 0.9224 25.4004
RL95-2 GDSC1; CTRP2 1.0866 6.1768 0.3049 27.5279
MFE-319 GDSC1; CTRP2 1.6763 4.233 1.5282 21.396
HEC-1-A CTRP2 1.9639 5.0054 1.6479 20.0808
JHUEM-3 CTRP2 2.3803 6.6946 1.4809 19.509
KLE GDSC1; CTRP2; CTRP1 2.519 7.1928 1.4194 19.4529
HEC-6 CTRP2 3.0657 6.2644 2.3773 14.1821
AN3-CA GDSC1; CTRP2 3.1143 7.7416 1.768 16.4647
HEC-59 CTRP2; CTRP1 3.3959 5.1245 3.174 10.3052
HEC-251 CTRP2 3.5911 6.3085 2.9004 10.7347
HEC-265 CTRP2 3.7144 5.0823 3.5296 7.9531
HEC-151 CTRP2; CTRP1 3.8761 5.9735 3.3467 8.3192
HEC-50B CTRP2 4.2606 5.9921 3.7147 5.7774
EN GDSC1; CTRP2 4.3806 5.3828 4.1164 3.8536
JHUEM-1 CTRP2 4.7022 11.5847 1.3307 14.6575
HEC-1-B CTRP2 4.7433 6.0629 4.1255 2.996
MFE-280 GDSC1 4.9804 10.7297 1.4132 16.074
EFE-184 CTRP2 6.7382 8.3171 4.2852 0.3157
HEC-108 CTRP2; CTRP1 8.4673 17.1373 1.3738 8.562
Ishikawa (Heraklio) 02 ER- CTRP2; CTRP1 3.8191 5.024 3.6667 7.2368
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 32 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BB65-RCC GDSC1 -0.8115 14.5327 -5.6666 52.8252
SW13 GDSC1 1.0327 3.3505 0.9131 37.7487
LB1047-RCC GDSC1 1.0535 5.6671 0.2139 40.335
SN12C GDSC1 1.1268 6.4404 -0.0243 40.5309
ACHN GDSC1; CTRP2 1.8832 3.7901 1.8255 19.7021
VMRC-RCW GDSC1; CTRP2 2.2444 10.172 -0.2256 25.9625
SW156 GDSC1 2.4205 5.2 1.8468 23.6336
TK-10 GDSC1 2.6621 11.3786 -0.8561 34.956
CAL-54 GDSC1; CTRP2 2.9216 7.5646 1.6569 17.391
HA7-RCC GDSC1 3.2516 10.664 0.0254 29.5176
BFTC-909 GDSC1; CTRP2 3.6517 8.1312 2.1057 13.8053
KMRC-3 CTRP2 4.091 9.7265 1.728 14.3495
786-O GDSC1; CTRP2 4.204 5.7412 3.7757 5.6686
UO-31 GDSC1; CTRP2 4.3832 10.8863 1.4075 15.0075
RXF 393L GDSC1 4.4904 15.974 -1.5834 30.5425
LB2241-RCC GDSC1 4.5147 10.9567 0.9407 20.3721
LB996-RCC GDSC1 4.613 9.7604 1.6134 15.9843
TUHR4TKB CTRP2 4.7875 8.324 3.0324 7.5079
KMRC-20 GDSC1; CTRP2 4.8966 7.444 3.5626 5.0688
KMRC-1 GDSC1; CTRP2 4.9522 13.0553 0.8035 16.1711
A-704 GDSC1 5.2958 7.2078 3.3038 2.2122
Caki-2 CTRP2 5.5495 7.1114 4.1994 1.4302
Caki-1 GDSC1; CTRP2 5.6745 9.2026 3.2838 4.9177
SNU-1272 CTRP2 5.8429 8.4537 3.7581 2.77
769-P GDSC1; CTRP2 5.899 9.6385 3.23 4.8014
A-498 GDSC1; CTRP2 5.9845 8.6103 3.7744 2.5298
TUHR14TKB CTRP2 6.1507 15.3796 0.5948 25.0612
VMRC-RCZ GDSC1; CTRP2 6.5002 11.372 2.8061 5.6503
RCC10RGB GDSC1; CTRP2; CTRP1 6.5658 9.8562 3.5683 2.7129
OS-RC-2 GDSC1; CTRP2 6.9286 13.6136 2.0221 8.1284
TUHR10TKB CTRP2 7.5689 18.9242 -0.1029 14.8079
KMRC-2 CTRP2 11.6591 22.4453 0.8316 6.8652
⏷ Show the Full List of 32 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 58 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-175 CTRP1 -2.5278 4.1397 -3.0233 76.0732
SW48 GDSC1; CTRP2 -0.8806 3.632 -1.1232 38.6289
HCC2998 GDSC1 0.0871 3.5739 -0.1619 49.0732
CL-34 CTRP1 0.2769 5.5044 -0.3397 59.2766
SNU-81 CTRP1 0.7196 8.7355 -1.1059 53.8413
COLO205 GDSC1; CTRP2 0.956 3.3293 0.8965 25.8926
SK-CO-1 CTRP2 1.2727 3.7007 1.1859 23.8739
LS180 GDSC1; CTRP2; CTRP1 1.2957 4.8916 0.9547 24.6939
LoVo GDSC1; CTRP2; CTRP1 1.3421 6.5065 0.4611 26.2923
HCT 116 GDSC1; CTRP2; CTRP1 1.8287 5.2198 1.439 21.3329
GP5d GDSC1 1.9387 8.2011 0.0057 35.6787
GP2d CTRP2 2.1683 8.2644 0.5802 23.4349
KM12 GDSC1; CTRP2; CTRP1 2.442 6.0268 1.8195 18.1362
SNU-C5 CTRP2; CTRP1 2.6281 7.245 1.5088 18.8189
HCT 15 GDSC1; CTRP2 2.7917 5.5044 2.3844 14.916
CaR-1 GDSC1 2.8098 7.889 0.9922 26.9348
COLO 320HSR GDSC1 2.8616 7.2327 1.3588 24.5777
SW626 GDSC1 3.1255 6.6888 1.8718 19.9956
SW620 GDSC1; CTRP2; CTRP1 3.2502 6.0797 2.6535 12.7008
SNU-C2A CTRP2 3.7625 9.3536 1.6139 15.5356
RKO GDSC1; CTRP2; CTRP1 3.7873 10.3598 1.1507 17.3807
SNU-C1 GDSC1; CTRP2 3.8328 7.1491 2.7504 10.7444
RCM-1 [Human ESC] GDSC1; CTRP2; CTRP1 3.9443 6.6803 3.0893 9.1878
HT-55 GDSC1; CTRP2; CTRP1 3.9775 5.8237 3.5167 7.3815
CL-11 GDSC1; CTRP2 4.044 9.7981 1.6504 14.7638
HT115 GDSC1; CTRP2; CTRP1 4.2173 9.1127 2.155 12.425
NCI-H508 CTRP2; CTRP1 4.2997 7.4152 3.0689 8.4549
SNU-C2B GDSC1 4.3177 7.8402 2.3378 11.8912
DLD-1 CTRP2 4.3565 7.5263 3.056 8.291
SNU-407 CTRP2 4.6215 11.0135 1.5481 13.9618
T84 GDSC1; CTRP2 4.6529 8.471 2.8453 8.5593
CL-40 CTRP1 4.7271 9.2859 2.5116 20.1973
SW1417 GDSC1; CTRP2 4.7326 5.8239 4.2355 2.5554
SNU-1040 CTRP1 4.7343 10.5768 1.8723 24.2494
SW837 GDSC1 4.7959 7.6199 2.8028 6.902
HCC-56 CTRP2 4.8065 7.02 3.7003 4.661
LS411N GDSC1; CTRP2 4.839 8.5683 2.9532 7.7411
LS123 GDSC1; CTRP2; CTRP1 4.9295 8.0743 3.2856 6.2645
NCI-H747 GDSC1; CTRP2 4.9794 11.8687 1.419 13.7667
CCK-81 GDSC1 4.9872 7.9892 2.7561 6.7349
HT-29 GDSC1; CTRP2; CTRP1 5.0103 5.8812 4.4412 1.2813
SNU-61 CTRP2; CTRP1 5.1464 12.4518 1.2751 14.0885
SNU-503 CTRP2 5.2506 26.6292 -5.7364 33.4145
SW480 CTRP1 5.3165 9.1249 3.0687 13.5659
OUMS-23 CTRP2 5.3392 7.772 3.7415 3.5565
LS1034 GDSC1; CTRP2 5.3663 10.1541 2.5843 8.3188
MDST8 GDSC1; CTRP2; CTRP1 5.5325 11.9975 1.809 11.2766
COLO 678 GDSC1; CTRP2; CTRP1 5.5901 8.9687 3.35 4.863
CW-2 GDSC1; CTRP2; CTRP1 5.7713 11.347 2.3141 8.8252
SW1463 GDSC1 5.8248 13.9075 0.4724 18.7912
SNU-1033 CTRP2 5.9281 15.9842 0.1232 16.7621
HCT 8 CTRP2; CTRP1 5.9606 7.1774 4.4053 0.4456
SW948 GDSC1; CTRP2; CTRP1 5.9976 31.6812 -7.6398 32.7645
COLO 320 CTRP2; CTRP1 6.2489 11.8695 2.4063 7.6917
NCI-H716 GDSC1; CTRP2 6.2819 9.6633 3.4706 3.333
LS513 GDSC1; CTRP2 6.5098 12.5627 2.2405 7.8804
SNU-C4 CTRP2; CTRP1 6.5461 7.545 4.5034 0.0677
C2BBe1 GDSC1; CTRP2 7.8574 20.1545 -0.4968 15.6164
⏷ Show the Full List of 58 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1 5.0731 9.9072 1.886 12.7239
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-7 GDSC1 -1.9698 4.8934 -2.7792 63.6068
HLE GDSC1 -0.7558 1.6203 -0.7821 58.9564
HLF CTRP2 0.5743 2.4841 -1.8426 1.1994
Huh-7 GDSC1 1.4234 5.4673 0.6855 36.1012
SNU-423 GDSC1; CTRP2 1.7493 4.711 1.4958 21.2836
PLC/PRF/5 CTRP2 1.7947 4.0553 1.6902 20.454
SNU-878 CTRP2 2.0618 6.0433 1.4016 20.7027
JHH-5 CTRP2 2.3193 5.4222 1.9023 18.089
Li-7 CTRP2 2.3746 6.1745 1.685 18.7481
Hep-G2/C3A GDSC1 2.4545 8.9365 0.1495 32.5507
JHH-4 GDSC1; CTRP2 2.5665 5.2381 2.2319 16.1406
SNU-398 GDSC1; CTRP2; CTRP1 3.178 9.276 1.1117 18.9537
Hep 3B2.1-7 GDSC1; CTRP2 4.0328 5.6953 3.6231 6.716
SNU-387 GDSC1; CTRP2 4.3555 11.3724 1.141 16.1035
HuH-1 GDSC1; CTRP2 4.3556 7.9946 2.8232 9.2652
JHH-2 GDSC1; CTRP2 4.4835 10.2683 1.8025 13.2203
SNU-182 CTRP2 4.6015 13.2322 0.4221 18.2575
JHH-6 GDSC1; CTRP2; CTRP1 4.9332 5.7921 4.4275 1.4658
SNU-886 CTRP2 5.2582 49.5405 -17.1846 40.3753
JHH-1 GDSC1; CTRP2 5.2875 8.2652 3.4605 5.538
SNU-475 GDSC1; CTRP2 5.9188 9.2957 3.4083 4.055
SK-HEP-1 GDSC1; CTRP2 6.3336 12.0922 2.3452 7.7267
Hep-G2 CTRP2; CTRP1 6.3778 11.4062 2.7202 6.2442
SNU-449 GDSC1; CTRP2; CTRP1 6.4676 8.9844 3.9009 1.6299
HuH-6 CTRP2 6.5723 18.4289 -0.5943 17.9653
SNU-761 CTRP2 7.396 16.8732 0.7719 12.1016
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 215 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-427 GDSC1 -3.0108 2.2041 -3.2462 74.1219
Lu-135 GDSC1 -2.1463 0.96 -2.1824 72.8391
SBC-3 GDSC1 -1.9232 0.7414 -1.9414 71.6398
Lu-134-A GDSC1 -1.5077 1.9553 -1.6006 65.7505
Calu-3 GDSC1; CTRP2 -1.1959 7.9806 -2.8193 42.9201
ABC-1 GDSC1 -1.195 1.7159 -1.2464 63.38
NCI-H211 GDSC1; CTRP2 -1.1693 3.9611 -1.5051 40.7047
NCI-H146 CTRP2 -1.0673 3.2623 -1.2577 39.7107
NCI-H1048 GDSC1 -0.9476 1.1686 -0.9588 61.4195
NCI-H1184 CTRP2 -0.7575 3.9244 -1.0494 37.9596
NCI-H526 GDSC1; CTRP2 -0.6435 1.1947 -0.646 36.3696
NCI-H1694 GDSC1; CTRP2; CTRP1 -0.6342 1.5911 -0.6434 36.3986
NCI-H3122 GDSC1 -0.5501 2.6374 -0.671 56.0397
NCI-H1105 CTRP2; CTRP1 -0.4603 2.5907 -0.5207 35.4047
NCI-H748 GDSC1 -0.3684 5.1263 -1.1164 53.0545
NCI-H187 GDSC1 -0.3414 2.2044 -0.3948 54.0018
NCI-H2009 GDSC1; CTRP2 -0.2625 2.0801 -0.2807 33.8805
NCI-H209 GDSC1 -0.2151 1.3171 -0.2183 52.6706
NCI-H2286 CTRP1 -0.1478 7.0569 -1.3414 60.135
LC-2/ad GDSC1 -0.1302 9.0957 -2.4749 50.7215
IST-SL2 GDSC1 -0.0506 6.4239 -1.2568 50.3733
NCI-H1963 GDSC1; CTRP1 0.1631 3.819 -0.0277 52.4461
DV-90 CTRP2 0.1783 6.7888 -0.8964 34.1517
NCI-H2081 GDSC1; CTRP2; CTRP1 0.214 5.7837 -0.4985 32.9795
SBC-5 GDSC1; CTRP2 0.2852 2.1904 0.2759 30.1975
NCI-H1876 GDSC1; CTRP1 0.358 3.1157 0.2884 50.575
NCI-H2804 GDSC1 0.3632 4.144 -0.0092 46.274
LCLC-97TM1 GDSC1; CTRP2 0.3758 5.6387 -0.279 31.7014
NCI-H1734 GDSC1; CTRP2 0.3843 3.4432 0.2728 29.88
NCI-H1703 GDSC1; CTRP2 0.5813 2.8818 0.545 28.313
NCI-H2087 GDSC1; CTRP2 0.5923 4.6827 0.2408 29.3072
NCI-H2595 GDSC1 0.5944 3.6738 0.3671 43.4003
LK-2 GDSC1 0.6374 3.2692 0.5009 42.6009
HOP-62 GDSC1; CTRP2 0.7166 6.1307 -0.0774 29.9534
HCC44 GDSC1; CTRP2 0.8522 5.1198 0.4018 27.9293
NCI-H23 GDSC1; CTRP2 0.9043 5.458 0.3539 27.9281
NCI-H2110 GDSC1; CTRP2; CTRP1 0.9053 4.2151 0.6969 26.8222
COLO 668 GDSC1; CTRP2; CTRP1 0.9395 2.7393 0.9254 25.9294
SK-MES-1 GDSC1; CTRP2 0.9668 5.3707 0.4496 27.4043
LB647-SCLC GDSC1 1.0228 9.8578 -1.6705 44.1432
NCI-H290 GDSC1 1.0826 6.013 0.1064 40.4562
NCI-H1304 GDSC1 1.1575 5.6008 0.3505 39.1755
NCI-H2170 GDSC1; CTRP2 1.2139 3.2436 1.1768 24.0961
NCI-H1341 CTRP2 1.2629 3.1991 1.2318 23.7489
Lu-99A GDSC1 1.3486 5.842 0.4563 37.5184
Lu-99 CTRP2 1.3907 8.2074 -0.1907 28.2411
NCI-H2591 GDSC1 1.4266 5.242 0.7761 35.6784
NCI-H810 GDSC1; CTRP2 1.4357 5.8242 0.8074 24.7118
NCI-H2369 GDSC1 1.4633 7.3888 -0.0929 38.6432
NCI-H1568 GDSC1; CTRP2 1.4867 4.6756 1.2185 23.0839
NCI-H2196 GDSC1; CTRP2 1.4893 9.0568 -0.4639 28.7979
SK-LU-1 GDSC1; CTRP2; CTRP1 1.4905 6.796 0.5067 25.6923
NCI-H1650 GDSC1; CTRP2 1.491 6.7216 0.5311 25.5275
Ms-1 GDSC1 1.5562 5.4427 0.8362 34.5662
COR-L95 GDSC1; CTRP2 1.562 8.2397 -0.0282 27.2184
RERF-LC-MS GDSC1; CTRP2 1.6119 6.4883 0.7509 24.3922
NCI-H1770 GDSC1 1.6153 5.879 0.7212 34.7277
SW1271 GDSC1; CTRP2 1.6401 8.0076 0.1531 26.3929
NCI-H1975 GDSC1 1.7377 4.9434 1.2218 31.4327
HCC15 GDSC1; CTRP2; CTRP1 1.7931 8.5063 0.0977 26.2166
SW1573 GDSC1; CTRP2 1.7973 12.0191 -1.5358 30.8699
NCI-H1930 CTRP1 1.8118 5.5423 1.3158 44.6193
NCI-H1437 GDSC1 1.8149 5.4585 1.1037 31.6192
EBC-1 GDSC1; CTRP2 1.8533 4.574 1.6441 20.4325
Lu-139 GDSC1 1.9398 4.8819 1.4615 28.8103
HCC78 GDSC1; CTRP2 1.9927 4.9604 1.6925 19.8318
ChaGo-K-1 GDSC1; CTRP2 2.0141 6.2933 1.2551 21.3853
NCI-H596 GDSC1; CTRP1 2.0821 6.3565 1.3081 34.9434
NCI-H64 GDSC1 2.0872 5.9731 1.1716 29.6682
UMC-11 GDSC1 2.1616 6.3661 1.0741 29.7925
EPLC-272H GDSC1; CTRP2 2.1679 7.6048 0.872 22.3773
NCI-H2228 GDSC1; CTRP2 2.3233 8.5505 0.6067 22.9223
SCLC-21H CTRP1 2.3381 8.1472 0.8119 41.6673
NCI-H2073 CTRP1 2.3482 12.5102 -1.2371 44.7304
HCC1438 CTRP2 2.3618 4.7681 2.149 17.0578
NCI-H1623 GDSC1; CTRP2 2.3979 7.3969 1.1993 20.5314
NCI-H2029 GDSC1; CTRP2 2.416 5.1383 2.1002 17.072
NCI-H1781 GDSC1; CTRP1 2.4679 8.3904 0.8322 34.6982
DMS 273 GDSC1; CTRP2 2.4862 8.0575 0.9948 21.0656
COR-L47 CTRP2 2.5021 8.6746 0.7282 22.0096
NCI-H847 GDSC1 2.5117 6.2867 1.4631 25.663
NCI-H358 GDSC1; CTRP2 2.5123 5.7532 1.993 17.1916
LXF 289 GDSC1; CTRP2; CTRP1 2.5308 8.0016 1.0724 20.7388
NCI-H1793 GDSC1; CTRP2 2.564 7.559 1.2977 19.7138
NCI-H1838 GDSC1; CTRP2 2.6732 4.7455 2.4949 14.8592
NCI-H2135 GDSC1 2.6765 6.0197 1.7503 22.9651
RERF-LC-A1 CTRP2 2.7283 7.4552 1.511 18.4606
DMS 53 GDSC1; CTRP2 2.7594 6.247 2.0633 16.2328
NCI-H510A GDSC1 2.7626 6.8694 1.4378 24.5667
NCI-H1339 CTRP2 2.7809 6.0427 2.1684 15.7688
HARA [Human squamous cell lung carcinoma] GDSC1; CTRP2 2.8208 9.1139 0.8362 20.793
LK2 CTRP2 2.8785 6.1413 2.2319 15.255
NCI-H1155 GDSC1; CTRP2 2.9222 5.0358 2.6834 13.4215
HCC366 CTRP2 2.9265 5.0641 2.6792 13.4239
NCI-H647 GDSC1; CTRP2 3.0147 8.7061 1.2178 18.8654
NCI-H2141 GDSC1; CTRP2; CTRP1 3.0301 7.4155 1.8412 16.476
COR-L51 CTRP2; CTRP1 3.0906 8.7936 1.2583 18.6052
NCI-H650 GDSC1; CTRP2 3.0938 8.0664 1.5964 17.1942
NCI-H522 GDSC1; CTRP2 3.1019 6.1781 2.4513 13.7957
NCI-H661 GDSC1; CTRP2 3.1258 7.9014 1.7051 16.6853
NCI-H2347 GDSC1 3.1266 6.9466 1.7478 20.843
NCI-H292 GDSC1; CTRP2 3.1318 8.7687 1.3017 18.2526
Lu-65 GDSC1; CTRP2 3.1874 6.145 2.5545 13.163
NCI-H1688 GDSC1 3.2534 6.0839 2.2853 16.4366
NCI-H838 GDSC1; CTRP2 3.2596 4.9811 3.0678 11.0036
NCI-H2405 GDSC1; CTRP2 3.2803 7.2486 2.1608 14.4832
NCI-H2373 GDSC1 3.3102 7.4647 1.6638 20.5951
NCI-H1581 GDSC1; CTRP2 3.3599 6.0109 2.7909 11.7753
DMS 454 CTRP2 3.3951 6.7003 2.5259 12.732
HOP-92 GDSC1; CTRP2 3.3981 13.0782 -0.5541 24.1283
NCI-H2030 GDSC1; CTRP2; CTRP1 3.4052 6.9105 2.4481 13.1096
PC-14 GDSC1; CTRP2 3.4318 6.6573 2.5824 12.4127
NCI-H841 GDSC1; CTRP2; CTRP1 3.4332 12.1055 -0.0324 22.4468
Calu-1 CTRP2 3.4763 8.3338 1.841 15.2895
NCI-H1355 GDSC1; CTRP2 3.4768 9.2311 1.4079 17.0106
NCI-H2023 GDSC1; CTRP2; CTRP1 3.4885 7.8653 2.0849 14.3667
NCI-H3255 GDSC1; CTRP1 3.51 8.5827 1.762 25.6327
IST-SL1 GDSC1 3.6447 10.2982 0.5501 25.6061
NCI-H2869 GDSC1 3.648 6.0512 2.668 11.8408
HCC2108 CTRP2; CTRP1 3.6773 6.2962 3.0005 10.2095
Sq-1 CTRP2; CTRP1 3.6812 5.0948 3.4935 8.2837
PaCa-3 GDSC1 3.7551 6.9693 2.3066 14.1783
MOR/CPR CTRP2 3.7629 5.1698 3.5514 7.7306
NCI-H520 GDSC1; CTRP2 3.7774 6.4949 3.0034 9.8496
NCI-H446 GDSC1; CTRP2 3.7856 8.672 1.9691 14.0513
NCI-H69 GDSC1; CTRP2 3.8756 8.4714 2.1508 13.1056
CPC-N GDSC1 3.9471 7.6603 2.1255 14.7852
COR-L23 GDSC1; CTRP1 3.9549 7.6675 2.6257 18.6501
NCI-H1092 GDSC1; CTRP2 3.9841 8.5704 2.2023 12.6507
NCI-H441 GDSC1; CTRP1 3.9935 9.2638 1.8787 22.9983
RERF-LC-KJ GDSC1; CTRP1 4.0261 7.4179 2.8139 17.1265
NCI-H460 GDSC1; CTRP2; CTRP1 4.0295 9.4498 1.8195 14.2004
NCI-H2171 GDSC1 4.0625 6.2825 2.9105 8.3647
LUDLU-1 CTRP2 4.0757 7.4306 2.8453 9.7892
Lu-165 GDSC1 4.088 11.8645 0.1409 25.8316
NCI-H1651 GDSC1 4.1266 19.3163 -3.5529 35.8646
NCI-H1299 GDSC1; CTRP2 4.1389 9.252 2.006 13.1161
NCI-H2722 GDSC1 4.2217 15.7606 -1.6965 31.6729
HCC1195 CTRP2; CTRP1 4.2251 8.1397 2.6437 10.3864
NCI-H2803 GDSC1 4.2268 10.135 1.1194 20.3692
HCC827 GDSC1; CTRP2; CTRP1 4.2352 8.5737 2.4381 11.2175
NCI-H1648 GDSC1 4.2511 10.8371 0.7884 22.1184
NCI-H1435 GDSC1; CTRP2; CTRP1 4.2527 8.1393 2.6689 10.2217
SBC-1 GDSC1 4.3041 6.6445 2.9219 7.4578
NCI-H1395 CTRP2 4.4137 9.8097 1.971 12.6778
DMS 114 GDSC1; CTRP2 4.4701 6.9033 3.4666 6.3305
HCC1588 CTRP2 4.4975 9.6028 2.1468 11.7833
LCLC-103H GDSC1; CTRP2 4.4986 6.371 3.7553 5.063
HCC95 CTRP2 4.5083 8.251 2.8304 8.9153
HCC33 GDSC1 4.5347 6.0579 3.3753 3.2935
NCI-H1869 GDSC1; CTRP2 4.6439 5.9717 4.084 3.3759
LOU-NH91 GDSC1; CTRP2 4.6558 9.4598 2.3537 10.6074
VMRC-LCD CTRP2 4.6702 9.5988 2.2964 10.8165
IA-LM GDSC1; CTRP2 4.7079 8.73 2.7625 8.7969
CAL-12T GDSC1; CTRP2; CTRP1 4.717 6.6121 3.8391 4.3498
NCI-H2444 GDSC1; CTRP2 4.7355 5.6833 4.3081 2.2442
NCI-H2291 GDSC1; CTRP2 4.7486 7.0136 3.6549 4.9653
NCI-H2461 GDSC1 4.7639 7.9628 2.6135 8.415
A-549 GDSC1; CTRP2 4.774 11.2682 1.5491 13.6532
T3M-10 CTRP2; CTRP1 4.7786 7.4323 3.4816 5.7296
NCI-H1385 CTRP2 4.7791 8.8447 2.7651 8.6465
HCC1359 CTRP1 4.8005 6.9563 3.7379 9.8706
NCI-H1436 GDSC1 4.8177 6.7432 3.2352 3.633
NCI-H2795 GDSC1 4.8203 14.8113 -0.7382 26.8682
NCI-H1666 GDSC1; CTRP2 4.8653 8.6161 2.9511 7.6997
NCI-H1836 GDSC1; CTRP1 4.8733 7.6078 3.4728 9.4864
NCI-H226 GDSC1; CTRP2 4.8817 15.8189 -0.6365 21.1968
NCI-H322 CTRP2 4.9077 8.0635 3.2621 6.3119
NCI-H82 GDSC1 4.9077 8.7048 2.3545 9.9122
HCC2279 CTRP2 4.9253 9.5846 2.5163 9.4058
HCC1833 CTRP2; CTRP1 4.9271 9.8621 2.3901 10.0153
NCI-H2126 CTRP2 4.9597 12.0119 1.3312 14.1482
NCI-H2227 GDSC1 4.9706 10.326 1.605 14.8928
NCI-H345 GDSC1 4.9914 5.9519 3.6749 0.5383
NCI-H2085 GDSC1; CTRP2 5.0031 14.4822 0.132 18.4633
NCI-H720 GDSC1 5.0344 6.3202 3.5464 1.1531
HCC4006 CTRP2; CTRP1 5.0521 8.6466 3.099 6.8206
DMS 79 GDSC1 5.0529 12.8128 0.4374 21.2312
NCI-H1944 GDSC1; CTRP2 5.0557 30.7867 -7.9759 34.5185
LC-1/sq-SF CTRP2 5.0625 6.7631 4.0331 2.7976
COLO 699 CTRP2; CTRP1 5.1225 8.4014 3.2773 5.9462
NCI-H2818 GDSC1 5.1272 7.345 3.1474 3.5712
COR-L88 GDSC1; CTRP2 5.1461 9.9333 2.5209 8.9753
RERF-LC-Ad1 CTRP2 5.1874 6.7777 4.1182 2.2434
NCI-H2106 CTRP2 5.189 10.2301 2.4071 9.3697
NCI-H2731 GDSC1 5.2076 8.0979 2.8488 5.5091
Calu-6 GDSC1; CTRP2 5.2129 8.6005 3.2372 5.8645
NCI-H196 GDSC1; CTRP2 5.2391 10.1767 2.4735 9.0038
NCI-H2122 GDSC1; CTRP2; CTRP1 5.326 10.4615 2.4116 9.1911
NCI-H524 GDSC1 5.352 9.2393 2.4033 8.3439
HCC2935 CTRP2; CTRP1 5.4023 9.7599 2.8197 7.3671
NCI-H2342 GDSC1; CTRP2; CTRP1 5.4668 12.0322 1.7403 11.6679
NCI-H1755 GDSC1; CTRP2; CTRP1 5.5133 9.6469 2.9599 6.598
KNS-62 CTRP2 5.5293 8.3146 3.6128 3.792
NCI-H1792 GDSC1; CTRP2 5.5732 13.0195 1.3207 13.0446
NCI-H1693 GDSC1; CTRP2 5.6354 14.3477 0.7085 15.231
NCI-H1993 GDSC1 5.6406 8.9693 2.713 5.4899
NCI-H1573 GDSC1 5.6971 7.5139 3.3754 1.2487
NCI-H1373 CTRP2 5.7081 9.5658 3.1306 5.4937
LC-1/sq GDSC1 5.8311 10.86 1.9498 10.2289
BEN GDSC1; CTRP2 6.0135 7.9227 4.1029 1.2915
NCI-H2172 GDSC1; CTRP1 6.0168 8.8294 3.7063 4.8105
NCI-H513 GDSC1 6.3453 14.2473 0.6747 16.3871
NCI-H1915 GDSC1; CTRP2; CTRP1 6.3529 11.5473 2.6352 6.6198
NCI-H1563 GDSC1; CTRP2 6.3785 14.6931 1.1049 12.4817
COR-L105 GDSC1; CTRP2 6.4701 11.0796 2.9252 5.2206
NCI-H727 GDSC1; CTRP2 6.6327 11.025 3.0562 4.4962
NCI-H889 CTRP2 6.6543 8.8505 4.0387 0.9757
RERF-LC-Sq1 GDSC1 6.7601 9.0039 3.2585 0.8277
NCI-H322M GDSC1 6.9869 9.157 3.2917 0.5856
SHP-77 GDSC1; CTRP2 7.1139 12.1567 2.8308 4.7672
HCC1171 CTRP2 7.5552 17.6004 0.5309 12.7076
RERF-LC-Ad2 CTRP2 7.5632 12.8623 2.7788 4.4439
EKVX GDSC1; CTRP2 8.0703 15.6619 1.7986 7.455
Hs 888.Lu CTRP2 7.272 15.6663 1.2693 10.4851
⏷ Show the Full List of 215 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1 4.6638 8.8818 2.0878 12.5796
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
H-STS CTRP2 -1.4335 1.5563 -1.461 41.7089
P-STS CTRP2 -0.6384 3.7439 -0.8828 37.0569
SYO-1 CTRP2 0.3658 4.6567 0.0005 30.8454
Cancer Drug Sensitivity Data Curated from 48 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 1.9045 8.4777 0.2169 25.4286
TOV-112D GDSC1; CTRP2 -1.6293 0.3756 -1.6309 42.9425
OC 314 GDSC1; CTRP2 -0.9838 1.6031 -1.0008 38.6853
A2780 GDSC1; CTRP2; CTRP1 -0.2798 9.2835 -2.3773 38.9924
OVKATE GDSC1; CTRP1 0.2471 8.1123 -1.3376 51.0241
OVCAR-8 GDSC1; CTRP2; CTRP1 0.4938 3.6504 0.3592 29.3053
COV434 CTRP2; CTRP1 0.9816 8.5118 -0.7385 31.1821
OVK18 CTRP2; CTRP1 1.2296 6.1371 0.4779 26.5735
TOV-21G GDSC1; CTRP2 1.3461 6.8541 0.0251 23.7978
Caov-3 GDSC1; CTRP2; CTRP1 1.7017 4.7325 1.4411 21.7108
TYK-nu GDSC1; CTRP2; CTRP1 1.7024 4.9444 1.3836 21.9146
SNU-119 CTRP2 1.9648 10.1771 -0.502 27.5753
DOV13 CTRP2 2.244 6.8408 1.2773 20.6563
MCAS CTRP2 2.3464 4.9138 2.0918 17.3116
JHOC-5 CTRP2; CTRP1 2.4262 8.0805 0.931 21.5435
OV-90 GDSC1; CTRP2; CTRP1 3.233 8.4299 1.569 17.0448
EFO-27 GDSC1; CTRP2; CTRP1 3.2506 5.8899 2.7321 12.3945
IGROV-1 GDSC1; CTRP2; CTRP1 3.4947 8.901 1.5937 16.3202
OV7 CTRP2; CTRP1 3.4967 6.6542 2.6566 12.044
SK-OV-3 GDSC1; CTRP2 3.5269 7.6546 2.2139 13.6627
OV56 CTRP2 3.5359 5.6582 3.1212 10.012
HEY A8 CTRP2 3.5834 9.1151 1.5643 16.1441
FU-OV-1 GDSC1; CTRP2 3.6068 6.5534 2.8059 11.0728
JHOS-2 CTRP2 3.7733 8.0519 2.2593 12.8953
ES-2 GDSC1 3.7969 5.7279 2.9615 8.9553
OVCAR-3 GDSC1 3.855 6.5273 2.6136 11.4474
SNU-8 CTRP2 4.0062 6.1154 3.4063 7.6531
OAW42 GDSC1; CTRP2; CTRP1 4.1495 7.118 3.0755 8.7635
OVCAR-5 GDSC1; CTRP2 4.3443 10.6484 1.4925 14.7524
ONCO-DG-1 CTRP2 4.3687 5.9499 3.8391 5.0104
RMUG-S CTRP1 4.4571 8.7128 2.5657 21.0349
RMG-I GDSC1; CTRP2; CTRP1 4.6472 7.7572 3.2074 7.1432
ES2 CTRP2 4.7286 7.9685 3.1607 7.0838
OVCAR-4 GDSC1; CTRP2; CTRP1 5.1903 8.0812 3.4894 4.9401
EFO-21 GDSC1; CTRP2 5.2177 10.3218 2.3842 9.4126
OAW28 GDSC1; CTRP2 5.2514 10.4541 2.3449 9.5138
COV362 CTRP2; CTRP1 5.2966 11.6028 1.8197 11.6588
Caov-4 GDSC1 5.4577 10.6449 1.8 12.1961
OVSAHO CTRP2 5.6033 11.0708 2.3117 9.0333
JHOM-1 CTRP2; CTRP1 5.7311 10.2858 2.807 6.8727
OVISE GDSC1; CTRP2 5.8248 11.9312 2.0537 9.7072
COV644 CTRP2; CTRP1 5.9162 7.5937 4.2082 1.0906
JHOS-4 CTRP1 6.5162 16.1759 0.489 24.4567
Kuramochi GDSC1; CTRP2 6.8638 11.6532 2.9088 4.7752
COV318 CTRP1 6.8667 12.1568 2.6879 11.4603
SNU-840 CTRP2; CTRP1 7.4557 13.7625 2.3111 6.391
OVTOKO GDSC1; CTRP2 7.7433 18.1192 0.411 12.8411
OVMANA CTRP1 9.5636 19.2189 1.0877 14.1788
⏷ Show the Full List of 48 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Aska-SS CTRP2 3.4299 6.1379 2.8097 11.5147
Yamato-SS CTRP2 4.5325 7.8602 3.0463 7.9604
Hs 633.T GDSC1 -2.7198 0.4441 -2.7467 77.9684
EW-8 GDSC1 -2.7046 -1.2646 -2.7046 82.7445
VA-ES-BJ GDSC1 -1.2812 2.4904 -1.4326 62.9779
SW872 GDSC1 -0.5437 1.6874 -0.5666 56.5249
A-204 GDSC1; CTRP2 -0.3541 7.6497 -1.7943 38.1232
MFH-ino GDSC1 -0.2395 4.4507 -0.7572 52.1958
G-401 GDSC1; CTRP2 -0.0968 6.8266 -1.2057 35.8982
TE 617.T CTRP2 0.0962 4.1956 -0.1808 32.3351
HT-1080 GDSC1; CTRP2; CTRP1 0.4793 10.309 -2.043 35.8914
G-402 GDSC1; CTRP2 1.4549 8.4242 -0.2189 28.1418
GCT GDSC1; CTRP2 1.5924 5.6571 1.0348 23.4246
Rh41 GDSC1; CTRP2 1.6719 4.8658 1.3694 21.9745
STS-0421 GDSC1 1.7514 10.2869 -1.1696 39.7634
SK-UT-1 GDSC1; CTRP2 1.9314 4.9888 1.6174 20.2898
Hs 729.T CTRP2 2.0658 7.2092 0.9365 22.422
TTC-709 CTRP2 2.14 9.3941 0.0356 25.3916
Rh30 GDSC1 2.1808 6.4614 1.0507 29.8138
TE 441.T GDSC1; CTRP2 2.1942 8.5421 0.4809 23.7178
KYM-1 GDSC1; CTRP2 2.2087 8.5008 0.5142 23.5607
RKN GDSC1; CTRP2; CTRP1 3.4966 6.3583 2.7887 11.5177
MES-SA GDSC1; CTRP2 3.7429 10.543 1.0104 17.936
SW982 GDSC1; CTRP2 3.898 8.0291 2.3875 12.0829
RD GDSC1; CTRP2 4.1961 10.1281 1.6218 14.55
BT-16 CTRP2 4.431 7.3452 3.2126 7.4766
BT-12 CTRP2 4.568 21.1724 -3.5755 29.054
SK-LMS-1 GDSC1; CTRP2 4.5888 10.0456 2.0039 12.1852
Tm87-16 CTRP2 4.6497 13.4789 0.3395 18.4509
SW684 GDSC1 5.8014 14.4355 0.1968 20.171
Rh18 CTRP2 6.2853 16.1035 0.3388 15.399
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 6.1767 8.0013 4.1555 0.9741
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H28 GDSC1; CTRP2 0.2079 4.3483 -0.0946 31.6809
NCI-H2052 GDSC1; CTRP2 2.7745 7.6747 1.4589 18.5423
MSTO-211H GDSC1; CTRP2 2.8899 7.0172 1.8705 16.6352
MPP 89 GDSC1; CTRP2 3.971 7.7931 2.5708 11.1617
ACC-MESO-1 CTRP2 4.3187 6.4964 3.5276 6.4115
IST-Mes1 GDSC1; CTRP2 4.5685 11.3381 1.3409 14.8875
NCI-H2452 GDSC1; CTRP2 4.5711 13.9288 0.0483 19.616
JL-1 CTRP2 7.2517 14.8195 1.6628 9.0447
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU145 GDSC1; CTRP2 0.2977 2.8846 0.2477 30.2503
22Rv1 GDSC1; CTRP2 1.2503 6.8546 0.2232 27.3056
LNCaP clone FGC GDSC1; CTRP2 2.9825 9.2313 0.9371 20.0125
VCaP GDSC1; CTRP2 3.2514 8.2915 1.6443 16.6164
PC-3 GDSC1 5.1582 9.4003 2.1936 10.3499
PaCa-3 CTRP2; CTRP1 5.4702 11.9219 1.7979 11.4321
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC1; CTRP2 1.1398 3.7513 1.0359 24.819
YD-15 CTRP2 1.7494 4.3046 1.5927 20.9387
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1 -2.3769 0.8558 -2.415 74.6812
Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
GSS CTRP2 -2.8232 3.433 -3.1891 50.7809
HGC-27 GDSC1; CTRP2 -0.8329 3.4656 -1.0404 38.2261
RF-48 GDSC1 -0.5855 5.7629 -1.5762 54.3771
AGS GDSC1; CTRP2; CTRP1 -0.4602 4.6673 -0.9008 36.5072
SNU-1 GDSC1; CTRP2 -0.1093 4.9734 -0.6046 34.3415
23132/87 GDSC1; CTRP2 -0.0622 2.7829 -0.1211 32.6789
GCIY GDSC1 -0.0166 5.7478 -0.9598 50.1333
NUGC-3 GDSC1; CTRP2 0.7691 3.6707 0.6505 27.3408
ECC10 GDSC1; CTRP2 1.1824 5.5397 0.6296 26.1103
MKN28 GDSC1 1.3797 6.6132 0.1644 38.3488
MKN1 GDSC1; CTRP2 1.7238 4.6131 1.4932 21.3717
SNU-601 CTRP2 1.877 5.4787 1.4037 21.2331
NCI-N87 GDSC1; CTRP2 1.9674 7.4908 0.7144 23.5067
ECC12 GDSC1; CTRP2 2.0265 4.4784 1.8556 19.1424
TMK-1 GDSC1 2.1311 5.3212 1.4928 27.5214
SNU-5 GDSC1; CTRP2 2.6269 4.7001 2.4561 15.1407
SNU-620 CTRP2 2.8609 5.195 2.5659 14.0367
NUGC-4 GDSC1; CTRP2 2.9748 7.7612 1.6202 17.3997
SNU-16 GDSC1; CTRP2 3.584 4.6953 3.5011 8.4485
MKN7 GDSC1; CTRP2 3.9109 7.1563 2.8221 10.2656
IM95 GDSC1; CTRP2 4.0018 10.1895 1.4186 15.778
LMSU CTRP2 4.0073 8.5075 2.2545 12.384
SNU-216 CTRP2 4.1115 5.7619 3.6734 6.3133
SNU-668 CTRP2 4.1592 8.2154 2.537 10.8814
SH-10-TC CTRP2 4.4943 4.9925 4.4019 2.4278
KATO III CTRP2 4.501 5.8852 3.9958 4.058
OCUM-1 GDSC1 4.579 7.8974 2.5103 9.7473
RERF-GC-1B GDSC1 4.6158 13.0047 0 24.6344
Hs 746.T GDSC1; CTRP2 4.7308 7.9926 3.1505 7.1223
HuG1-N CTRP2 4.8686 7.5237 3.4999 5.3856
HSC-39 GDSC1 5.1349 7.7873 2.9479 4.9674
TGBC11TKB GDSC1 5.3649 10.0723 2.0124 11.0321
GSU CTRP2 5.5897 6.2374 4.5928 0.1338
MKN74 CTRP2; CTRP1 5.6095 8.1847 3.7444 3.2261
SNU-719 CTRP2 5.6494 12.0419 1.8656 10.7626
MKN45 GDSC1; CTRP2 5.9362 7.1678 4.3826 0.4685
SCH GDSC1 6.0534 7.3443 3.5839 0.2195
Fu97 GDSC1; CTRP2 6.2811 11.2198 2.7307 6.2592
KE-39 CTRP2 8.0924 17.299 1.0414 10.1577
SNU-685 CTRP2 4.1935 8.4094 2.4722 11.0755
SNU-1077 CTRP2 5.0027 6.5764 4.0799 2.7042
SNG-M GDSC1; CTRP2; CTRP1 5.3533 14.2568 0.5408 16.4318
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IHH-4 GDSC1 -2.7983 -0.0949 -2.8081 80.1251
TT2609-C02 GDSC1; CTRP2 -0.759 2.4465 -0.8219 37.3291
FTC-238 CTRP2 0.3608 3.7917 0.1894 30.2373
ML-1 [Human leukemia] GDSC1; CTRP2 0.4883 4.2445 0.2348 29.6661
KMH-2 GDSC1 0.5697 4.3629 0.1513 44.1745
CAL-62 GDSC1; CTRP2 0.5879 3.4366 0.4915 28.4727
ASH-3 GDSC1 0.5888 2.9865 0.497 43.0237
8505C GDSC1; CTRP2 1.1118 4.7855 0.7803 25.7997
SW579 CTRP2 1.4858 4.1255 1.3432 22.6466
FTC-133 GDSC1; CTRP2 1.8551 4.3755 1.6923 20.256
CGTH-W-1 GDSC1; CTRP2 1.8909 4.3324 1.7405 19.9733
BHT-101 GDSC1; CTRP2 2.2321 4.9154 1.9666 18.1121
B-CPAP GDSC1; CTRP2 3.8284 8.3227 2.1794 13.0956
HTC-C3 GDSC1 3.848 11.242 0.2516 26.2198
8305C GDSC1; CTRP2 3.972 7.5125 2.7082 10.5923
K5 GDSC1 4.5367 15.3922 -1.2553 29.4444
TT GDSC1; CTRP2 5.6486 7.7006 3.9873 2.124
WRO GDSC1 5.8003 12.0337 1.3665 13.9813
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BB30-HNC GDSC1 -3.4897 2.0333 -3.733 76.4273
JHU-011 GDSC1 -1.6291 -0.0396 -1.6297 70.0326
NCI-H3118 GDSC1 -1.0702 1.4328 -1.0965 62.4947
PCI-06A GDSC1 -0.8147 2.1285 -0.8863 59.1526
JHU-029 GDSC1 -0.7432 5.1546 -1.5321 55.8508
KON GDSC1 -0.4619 2.4652 -0.5523 55.2182
OSC-20 GDSC1 -0.4347 1.6793 -0.4536 55.2604
PCI-04B GDSC1 -0.093 3.3215 -0.3015 50.9974
Ca9-22 GDSC1 0.0718 3.2834 -0.1147 49.212
SAS GDSC1 0.5226 4.248 0.1344 44.6094
FaDu GDSC1; CTRP2 0.5329 3.1006 0.4741 28.7117
HO-1-u-1 GDSC1 0.5716 4.2716 0.1809 44.0885
HSC-4 GDSC1; CTRP2 1.2038 3.9623 1.069 24.4994
HO-1-N-1 GDSC1 1.2181 5.4219 0.4846 38.2797
CAL-33 GDSC1; CTRP2 1.27 5.5249 0.7296 25.4896
PCI-15A GDSC1 1.7352 5.0488 1.1796 31.6843
KOSC-2 GDSC1 1.8542 10.812 -1.3259 39.6039
HSC-2 GDSC1; CTRP2 1.8829 4.5257 1.6881 20.1838
PE/CA-PJ49 CTRP2 2.0437 5.9495 1.4172 20.6964
SCC-9 GDSC1; CTRP2; CTRP1 2.3082 7.7218 0.9713 21.7102
PE/CA-PJ15 GDSC1; CTRP2 2.6731 6.8473 1.7213 17.7906
HSC-3 GDSC1; CTRP2 2.7418 5.5489 2.3146 15.3217
OSC-19 GDSC1 2.7676 8.7644 0.5262 29.4679
CAL-27 GDSC1; CTRP2 2.9148 4.6302 2.7875 13.0668
SNU-1076 CTRP2 2.9704 6.7285 2.0797 15.6019
BICR 78 GDSC1 2.9827 7.4557 1.3652 23.9714
PE/CA-PJ41 (clone D2) CTRP2 3.2002 9.2431 1.1403 18.7084
BICR 10 GDSC1 3.2103 6.4932 2.0466 18.3768
PE/CA-PJ34 (clone C12) CTRP2 3.2445 8.1024 1.7271 16.3043
BHY GDSC1; CTRP2 3.284 7.6216 1.9916 15.1513
SCC-15 GDSC1 3.4115 10.1749 0.4094 27.2073
BICR 18 CTRP2 3.484 7.7519 2.126 14.1219
UPCI-SCC-090 GDSC1 3.6105 7.2847 2.0227 16.8448
SCC-25 GDSC1; CTRP2 3.7913 10.9505 0.8528 18.4217
BICR 31 GDSC1; CTRP2 3.8384 14.4489 -0.8429 24.0031
YD-8 CTRP2 3.8453 6.9672 2.849 10.311
Detroit 562 GDSC1; CTRP2 4.0165 7.3931 2.808 10.0783
BICR 6 CTRP2 4.1207 8.4225 2.3998 11.5344
SKN-3 GDSC1 4.1801 9.5394 1.3789 18.9809
SNU-1066 CTRP2 4.241 10.8672 1.2934 15.7544
BICR 56 CTRP2 4.3769 9.4396 2.1235 12.1287
YD-10B CTRP2 4.3799 7.5846 3.0482 8.2734
SNU-899 CTRP2 4.4237 8.5958 2.5846 10.1181
SCC-4 GDSC1; CTRP2 4.5395 10.0201 1.9745 12.4053
BB49-HNC GDSC1 4.5517 7.1648 2.8505 7.2411
PCI-38 GDSC1 5.0491 8.3936 2.6041 7.6897
DOK GDSC1 5.0979 8.8986 2.3944 9.0842
JHU-022 GDSC1 5.1618 12.1078 0.8689 18.6717
PCI-30 GDSC1 5.2516 8.4361 2.7182 6.3431
SNU-1214 CTRP2 5.3278 7.5271 3.8531 3.1154
BICR 16 CTRP2 5.349 9.8669 2.7136 7.8122
SNU-46 CTRP2 5.9345 10.3226 2.9233 5.9941
BICR 22 GDSC1; CTRP2 6.4716 28.5887 -5.7265 29.475
LB771-HNC GDSC1 7.0008 20.9056 -2.1011 25.4673
SAT [Human HNSCC] GDSC1 7.2334 9.8028 3.1532 0.8917
SNU-1041 CTRP2 7.657 13.035 2.7558 4.4246
⏷ Show the Full List of 56 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
647V GDSC1; CTRP2 -0.6534 1.5607 -0.6623 36.457
5637 GDSC1; CTRP2 0.8178 6.0373 0.0649 29.1692
JMSU-1 CTRP2 0.8891 3.0926 0.8495 26.2712
RT-112 GDSC1; CTRP2 1.208 3.1675 1.177 24.1149
UM-UC-3 GDSC1; CTRP2 1.6384 4.1368 1.5063 21.5927
UM-UC-1 CTRP2 1.8482 5.6659 1.3085 21.6677
VM-CUB-1 CTRP2 1.9795 5.1949 1.6073 20.1816
BFTC-905 GDSC1; CTRP2 2.2221 4.8818 1.9653 18.1474
J82 GDSC1; CTRP2 2.3695 4.8839 2.1256 17.1191
CAL-29 GDSC1; CTRP2 2.3847 5.0304 2.0993 17.169
639V GDSC1; CTRP2 2.5581 3.8259 2.5352 15.0816
SW1710 GDSC1; CTRP2 3.0089 6.8104 2.0834 15.4864
SCaBER CTRP2 3.1089 9.9735 0.7011 20.5775
TCCSUP GDSC1; CTRP2 3.2509 6.4545 2.4878 13.2562
253J CTRP2 3.2614 8.7867 1.4179 17.4846
U-BLC1 CTRP2 3.7952 11.2746 0.6958 18.995
RT-4 GDSC1; CTRP2 4.0669 8.7539 2.1875 12.5285
SW780 GDSC1 4.0876 16.0835 -1.9689 32.7792
KMBC-2 CTRP2 4.1818 10.1801 1.5834 14.7343
HT-1197 GDSC1 4.3928 13.3303 -0.3419 26.7668
BC-3C CTRP2 4.5483 7.8281 3.076 7.803
253J-BV CTRP2 4.7642 9.4986 2.4257 10.0935
T24 GDSC1; CTRP2 4.8536 8.957 2.771 8.4777
KU-19-19 GDSC1; CTRP2 5.2588 8.7201 3.2133 5.8853
HT-1376 GDSC1; CTRP2 5.3164 8.2698 3.4799 4.6768
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NT2-D1 GDSC1 -5.9502 -3.184 -5.9512 96.9743
PA-1 GDSC1 -2.976 -1.8538 -2.976 86.3933
KGN GDSC1 -1.9881 9.9975 -4.7765 58.6403
SiSo GDSC1 -1.4648 0.3432 -1.4669 67.8614
NEC8 GDSC1 -0.7816 2.0209 -0.8403 58.9113
C-33 A GDSC1 -0.6756 1.7716 -0.7086 57.9663
ME-180 GDSC1 -0.0071 2.873 -0.125 50.0812
DoTc2 4510 GDSC1 0.0141 2.9403 -0.1131 49.8402
BPH-1 GDSC1 0.1364 3.3766 -0.0641 48.5077
HT-3 GDSC1 0.2916 3.5451 0.0675 46.8158
C-4-I GDSC1 0.4318 3.8506 0.1457 45.3767
MS751 GDSC1 0.6678 3.8428 0.4052 42.6681
SW954 GDSC1 0.7006 5.8866 -0.2473 43.9835
HEC-1 GDSC1 1.0324 4.4162 0.6388 38.9919
JEG-3 GDSC1 1.0501 9.5161 -1.4835 43.7686
DSH1 GDSC1 1.161 4.8519 0.6334 38.0924
Ca Ski GDSC1 1.2021 5.5647 0.4121 38.6551
SW756 GDSC1 1.6632 5.3116 1.0015 33.0804
CAL-39 GDSC1 1.9562 7.4877 0.3562 34.2868
SKN GDSC1 2.1388 4.7574 1.7212 26.0164
LB831-BLC GDSC1 2.4811 5.3322 1.8548 23.2586
SW962 GDSC1 3.6097 8.6257 1.3544 21.3226
OVMIU GDSC1 4.031 10.9873 0.5322 24.2236
OMC-1 [Human cervical carcinoma] GDSC1 4.5251 10.6777 1.0881 19.5047
JAR GDSC1 4.6448 6.4403 3.2663 3.8253
SKG-IIIa GDSC1 4.8304 10.3279 1.4986 16.0133
HeLa GDSC1; CTRP2 4.8514 5.8299 4.3323 1.9159
NCC-IT GDSC1 4.88 23.5105 -5.0319 36.2308
SiHa GDSC1 5.714 9.9957 2.2819 8.2889
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Etoposide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Decreased metabolism of Etoposide caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [29]
Armodafinil DMGB035 Minor Increased metabolism of Etoposide caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [30]
LEE011 DMMX75K Moderate Decreased metabolism of Etoposide caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [31]
Doxorubicin DMVP5YE Minor Increased renal excretion of Etoposide caused by Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [32]
Coadministration of a Drug Treating the Disease Different from Etoposide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Midostaurin DMI6E0R Moderate Decreased clearance of Etoposide due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [33]
Arn-509 DMT81LZ Moderate Accelerated clearance of Etoposide due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [33]
Gilteritinib DMTI0ZO Moderate Decreased clearance of Etoposide due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [29]
Dronedarone DMA8FS5 Moderate Decreased clearance of Etoposide due to the transporter inhibition by Dronedarone. Angina pectoris [BA40] [34]
Posaconazole DMUL5EW Moderate Decreased metabolism of Etoposide caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [33]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Etoposide and Roflumilast. Asthma [CA23] [33]
Ofloxacin DM0VQN3 Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [35]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Etoposide caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [36]
Sparfloxacin DMB4HCT Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [35]
Gemifloxacin DMHT34O Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [35]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [35]
ABT-492 DMJFD2I Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [35]
Levofloxacin DMS60RB Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [35]
Lomefloxacin DMVRH9C Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [35]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Etoposide caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [37]
Erdafitinib DMI782S Moderate Decreased clearance of Etoposide due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [38]
Lapatinib DM3BH1Y Moderate Decreased clearance of Etoposide due to the transporter inhibition by Lapatinib. Breast cancer [2C60-2C6Y] [39]
Tucatinib DMBESUA Moderate Decreased metabolism of Etoposide caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [40]
PF-04449913 DMSB068 Moderate Decreased clearance of Etoposide due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [33]
Anisindione DM2C48U Moderate Increased plasma concentration of Etoposide and Anisindione due to competitive binding of plasma proteins. Coagulation defect [3B10] [41]
Mifepristone DMGZQEF Moderate Decreased metabolism of Etoposide caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [29]
Ivacaftor DMZC1HS Moderate Decreased clearance of Etoposide due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [42]
MK-8228 DMOB58Q Moderate Decreased metabolism of Etoposide caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [43]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Etoposide caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [44]
Primidone DM0WX6I Moderate Increased metabolism of Etoposide caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Etoposide caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Cenobamate DM8KLU9 Moderate Increased metabolism of Etoposide caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [46]
Stiripentol DMMSDOY Moderate Decreased metabolism of Etoposide caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [47]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Etoposide caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Rufinamide DMWE60C Moderate Increased metabolism of Etoposide caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [33]
Phenobarbital DMXZOCG Moderate Increased metabolism of Etoposide caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Tazemetostat DMWP1BH Moderate Increased metabolism of Etoposide caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [48]
Itraconazole DMCR1MV Moderate Decreased metabolism of Etoposide caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [49]
Boceprevir DMBSHMF Moderate Decreased metabolism of Etoposide caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [50]
Telaprevir DMMRV29 Moderate Decreased metabolism of Etoposide caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [51]
GS-5885 DMSL3DX Moderate Decreased clearance of Etoposide due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [52]
Rifapentine DMCHV4I Moderate Increased metabolism of Etoposide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [53]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Etoposide and Brentuximab vedotin. Hodgkin lymphoma [2B30] [54]
Saquinavir DMG814N Moderate Decreased metabolism of Etoposide caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [55]
Etravirine DMGV8QU Moderate Increased metabolism of Etoposide caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Etoposide and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [57]
Darunavir DMN3GCH Moderate Decreased metabolism of Etoposide caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [58]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Etoposide and Teriflunomide. Hyper-lipoproteinaemia [5C80] [59]
Conivaptan DM1V329 Moderate Decreased metabolism of Etoposide caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [60]
Tolvaptan DMIWFRL Moderate Decreased clearance of Etoposide due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [29]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Etoposide and Denosumab. Low bone mass disorder [FB83] [61]
Brigatinib DM7W94S Moderate Increased metabolism of Etoposide caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [62]
Ceritinib DMB920Z Moderate Decreased metabolism of Etoposide caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [33]
PF-06463922 DMKM7EW Moderate Increased metabolism of Etoposide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [63]
Capmatinib DMYCXKL Moderate Decreased clearance of Etoposide due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [64]
Selpercatinib DMZR15V Moderate Decreased metabolism of Etoposide caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [33]
Idelalisib DM602WT Moderate Decreased metabolism of Etoposide caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [65]
IPI-145 DMWA24P Moderate Decreased metabolism of Etoposide caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [66]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Etoposide caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [33]
Lasmiditan DMXLVDT Moderate Decreased clearance of Etoposide due to the transporter inhibition by Lasmiditan. Migraine [8A80] [67]
Exjade DMHPRWG Moderate Decreased metabolism of Etoposide caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [68]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Etoposide and Thalidomide. Multiple myeloma [2A83] [69]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Etoposide and Tecfidera. Multiple sclerosis [8A40] [70]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Etoposide and Siponimod. Multiple sclerosis [8A40] [29]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Etoposide and Fingolimod. Multiple sclerosis [8A40] [71]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Etoposide and Ocrelizumab. Multiple sclerosis [8A40] [72]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Etoposide and Ozanimod. Multiple sclerosis [8A40] [33]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Etoposide caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [33]
Nilotinib DM7HXWT Moderate Decreased metabolism of Etoposide caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [73]
Dasatinib DMJV2EK Moderate Decreased metabolism of Etoposide caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [74]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Etoposide and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [75]
Rolapitant DM8XP26 Moderate Decreased clearance of Etoposide due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [76]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Etoposide caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [77]
Abametapir DM2RX0I Moderate Decreased metabolism of Etoposide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [78]
Lefamulin DME6G97 Moderate Decreased metabolism of Etoposide caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [79]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Etoposide caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [80]
Enzalutamide DMGL19D Moderate Accelerated clearance of Etoposide due to the transporter induction by Enzalutamide. Prostate cancer [2C82] [81]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Etoposide and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [82]
Gatifloxacin DMSL679 Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [35]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Etoposide and Canakinumab. Rheumatoid arthritis [FA20] [83]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Etoposide and Rilonacept. Rheumatoid arthritis [FA20] [83]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Etoposide and Golimumab. Rheumatoid arthritis [FA20] [84]
Leflunomide DMR8ONJ Major Additive myelosuppressive effects by the combination of Etoposide and Leflunomide. Rheumatoid arthritis [FA20] [59]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Etoposide when combined with Anthrax vaccine. Sepsis [1G40-1G41] [85]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Etoposide caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [86]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Etoposide caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [33]
Pitolisant DM8RFNJ Moderate Increased metabolism of Etoposide caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [33]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Etoposide caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [87]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Etoposide and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [82]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Etoposide and Azathioprine. Transplant rejection [NE84] [29]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Etoposide and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [82]
Cinoxacin DM4EWNS Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [35]
Nalidixic acid DMRM0JV Minor Decreased absorption of Etoposide due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [35]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Etoposide and Ganciclovir. Virus infection [1A24-1D9Z] [29]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Etoposide and Valganciclovir. Virus infection [1A24-1D9Z] [29]
⏷ Show the Full List of 90 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Sodium citrate anhydrous E00102 6224 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Eisenoxyd E00585 56841934 Colorant
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Dextran E00466 4125253 Lyophilization aid
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Etoposide 50 mg capsule 50 mg Oral Capsule Oral
Etoposide Phosphate eq 100mg base/vial injectable eq 100mg base/vial Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Etoposide FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6815).
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 075635.
4 ClinicalTrials.gov (NCT04356690) Etoposide in Patients With COVID-19 Infection. U.S. National Institutes of Health.
5 BDDCS applied to over 900 drugs
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9 Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
10 Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
11 Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30.
12 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
13 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
14 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
15 Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
16 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
17 Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
20 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
21 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
22 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
23 Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8.
24 Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
25 Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. J Biol Chem. 2007 Oct 12;282(41):29847-54.
26 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
27 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
28 Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells. Arch Toxicol. 2018 Apr;92(4):1507-1524.
29 Cerner Multum, Inc. "Australian Product Information.".
30 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
31 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
32 Cummings J, Forrest GJ, Cunningham D, Gilchrist NL, Soukop M "Influence of polysorbate 80 (tween 80) and etoposide (VP-16-213 on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients." Cancer Chemother Pharmacol 17 (1987): 80-4. [PMID: 3698181]
33 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
34 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
35 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
36 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
37 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
38 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
39 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
40 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
41 Le AT, Hasson NK, Lum BL "Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy." Ann Pharmacother 31 (1997): 1006-8. [PMID: 9296241]
42 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
43 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
44 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
45 Rodman JH, Murry DJ, Madden T, Santana VM "Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation." J Clin Oncol 12 (1994): 2390-7. [PMID: 7964955]
46 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
47 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
48 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
49 Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
50 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
51 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
52 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
53 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
54 Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
55 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
56 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
57 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
58 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
59 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
60 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
61 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
62 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
63 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
64 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
65 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
66 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
67 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
68 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
69 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
70 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
71 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
72 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
73 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
74 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
75 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
76 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
77 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
78 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
79 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
80 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
81 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
82 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
83 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
84 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
85 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
86 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
87 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.